CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | beta-lactam |
|
Accession: | CHEBI:35627
|
browse the term
|
Definition: | A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon. |
Synonyms: | related_synonym: | Formula=C3H2NOR3; SMILES=C1(C(N(*)C1*)=O)*; a beta-lactam; beta-lactams |
| alt_id: | CHEBI:10426; CHEBI:13203; CHEBI:22845 |
| xref: | KEGG:C01866; Wikipedia:Beta-lactam |
|
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
increases expression |
ISO |
7-aminocephalosporanic acid results in increased expression of AMPD3 mRNA |
CTD |
PMID:24211530 |
|
NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
ISO |
7-aminocephalosporanic acid results in increased expression of FTH1 mRNA |
CTD |
PMID:24211530 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
increases expression |
ISO |
7-aminocephalosporanic acid results in increased expression of FTL mRNA |
CTD |
PMID:24211530 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
7-aminocephalosporanic acid results in increased expression of GCLM mRNA |
CTD |
PMID:24211530 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
7-aminocephalosporanic acid results in increased expression of HMOX1 mRNA |
CTD |
PMID:24211530 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
ISO |
7-aminocephalosporanic acid results in increased expression of MYC mRNA |
CTD |
PMID:24211530 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
7-aminocephalosporanic acid results in increased expression of NQO1 mRNA |
CTD |
PMID:24211530 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Sel1l3 |
SEL1L family member 3 |
increases expression |
ISO |
7-aminocephalosporanic acid results in increased expression of SEL1L3 mRNA |
CTD |
PMID:24211530 |
|
NCBI chr14:57,775,515...57,882,076
Ensembl chr14:57,775,501...57,882,644
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
7-aminocephalosporanic acid results in increased expression of SLC7A11 mRNA |
CTD |
PMID:24211530 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
7-aminocephalosporanic acid results in increased expression of SQSTM1 mRNA |
CTD |
PMID:24211530 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Syne2 |
spectrin repeat containing nuclear envelope protein 2 |
decreases expression |
ISO |
7-aminocephalosporanic acid results in decreased expression of SYNE2 mRNA |
CTD |
PMID:24211530 |
|
NCBI chr 6:94,537,088...94,848,085
Ensembl chr 6:94,537,088...94,848,064
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
decreases expression |
ISO |
7-aminocephalosporanic acid results in decreased expression of TNNT2 mRNA |
CTD |
PMID:24211530 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
7-aminocephalosporanic acid results in increased expression of TXNRD1 mRNA |
CTD |
PMID:24211530 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression |
ISO |
Amoxicillin results in increased expression of AKR1B10 mRNA |
CTD |
PMID:28444390 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
Amoxicillin results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:36529298 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Amh |
anti-Mullerian hormone |
increases expression |
ISO |
Amoxicillin results in increased expression of AMH mRNA |
CTD |
PMID:36529298 |
|
NCBI chr 7:8,906,776...8,909,192
Ensembl chr 7:8,906,836...8,909,282
|
|
G |
Aqp5 |
aquaporin 5 |
decreases expression |
EXP |
Amoxicillin results in decreased expression of AQP5 protein |
CTD |
PMID:30031112 |
|
NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Casp3 |
caspase 3 |
increases expression |
ISO |
Amoxicillin results in increased expression of CASP3 mRNA; Amoxicillin results in increased expression of CASP3 protein |
CTD |
PMID:36529298 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
decreases activity |
EXP |
Amoxicillin results in decreased activity of CAT protein |
CTD |
PMID:26429924 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
decreases expression |
ISO |
Amoxicillin results in decreased expression of CXCL10 mRNA |
CTD |
PMID:25091725 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Amoxicillin results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:36529298 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
increases expression |
ISO |
Amoxicillin results in increased expression of CYP11B2 |
CTD |
PMID:17822730 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Amoxicillin results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:36529298 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression |
ISO |
Amoxicillin results in increased expression of CYP19A1 |
CTD |
PMID:17822730 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
multiple interactions decreases activity |
ISO |
Amoxicillin inhibits the reaction [CYP2C8 protein results in decreased methylation of Aminopyrine] Amoxicillin results in decreased activity of CYP2C8 protein |
CTD |
PMID:26763401 |
|
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
decreases expression |
ISO |
Amoxicillin results in decreased expression of GFRA1 mRNA |
CTD |
PMID:36529298 |
|
NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity |
ISO |
Amoxicillin results in decreased activity of GSR protein |
CTD |
PMID:32196862 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
ISO |
Amoxicillin results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:36529298 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation |
ISO |
Amoxicillin results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:36529298 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
Amoxicillin results in decreased expression of MKI67 mRNA; Amoxicillin results in decreased expression of MKI67 protein |
CTD |
PMID:36529298 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
Amoxicillin results in increased expression of NQO1 mRNA |
CTD |
PMID:28444390 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
decreases expression |
ISO |
Amoxicillin results in decreased expression of NR5A1 mRNA |
CTD |
PMID:36529298 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
ISO |
Amoxicillin results in decreased expression of PCNA mRNA; Amoxicillin results in decreased expression of PCNA protein |
CTD |
PMID:36529298 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
affects expression |
ISO |
Amoxicillin affects the expression of HLA-DQB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597
|
|
G |
Slc51a |
solute carrier family 51 member A |
increases expression |
ISO |
Amoxicillin results in increased expression of SLC51A mRNA |
CTD |
PMID:34767876 |
|
NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
ISO |
Amoxicillin results in increased expression of SRXN1 mRNA |
CTD |
PMID:28444390 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression |
ISO |
Amoxicillin results in decreased expression of STAR mRNA; Amoxicillin results in decreased expression of STAR protein |
CTD |
PMID:36529298 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Zbtb16 |
zinc finger and BTB domain containing 16 |
decreases expression |
ISO |
Amoxicillin results in decreased expression of ZBTB16 mRNA; Amoxicillin results in decreased expression of ZBTB16 protein |
CTD |
PMID:36529298 |
|
NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCA1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCB11 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCB1A mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC2 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
decreases expression multiple interactions |
ISO |
Ampicillin results in decreased expression of ABCC3 mRNA [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCC3 mRNA |
CTD |
PMID:21632981 PMID:36464106 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases transport |
ISO |
ABCC4 protein results in increased transport of Ampicillin |
CTD |
PMID:17939016 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCG2 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of ABCG2 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCG5 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of ABCG5 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACAT2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Acat2l1 |
acetyl-CoA acetyltransferase 2-like 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACAT2L1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:47,803,822...47,829,012
Ensembl chr 1:47,803,813...47,829,151
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACE2 protein |
CTD |
PMID:30545405 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
decreases expression |
ISO |
Ampicillin results in decreased expression of AGER mRNA |
CTD |
PMID:24747151 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Ahsg |
alpha-2-HS-glycoprotein |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of AHSG protein |
CTD |
PMID:30545405 |
|
NCBI chr11:78,121,388...78,127,998
Ensembl chr11:78,117,918...78,145,999
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
decreases expression |
ISO |
Ampicillin results in decreased expression of AKR1B10 mRNA |
CTD |
PMID:21632981 PMID:26198647 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
decreases expression |
ISO |
Ampicillin results in decreased expression of AKR1C2 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ALDOA protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Aldob |
aldolase, fructose-bisphosphate B |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ALDOB protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:63,889,046...63,902,116
|
|
G |
Amot |
angiomotin |
increases expression |
ISO |
Ampicillin results in increased expression of AMOT mRNA |
CTD |
PMID:21632981 |
|
NCBI chr X:108,982,399...109,041,265
Ensembl chr X:108,984,022...109,041,272
|
|
G |
Ankrd1 |
ankyrin repeat domain 1 |
increases expression |
ISO |
Ampicillin results in increased expression of ANKRD1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
decreases expression |
ISO |
Ampicillin results in decreased expression of AQP3 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Arg1 |
arginase 1 |
increases expression |
ISO |
Ampicillin results in increased expression of ARG1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arg2 |
arginase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of ARG2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
increases expression |
ISO |
Ampicillin results in increased expression of ARHGDIA mRNA |
CTD |
PMID:21632981 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Arpc3 |
actin related protein 2/3 complex, subunit 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ARPC3 protein |
CTD |
PMID:30545405 |
|
NCBI chr12:34,172,780...34,186,651
Ensembl chr12:34,172,780...34,186,651
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
decreases expression |
ISO |
Ampicillin results in decreased expression of ARRDC3 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978
|
|
G |
Arrdc4 |
arrestin domain containing 4 |
decreases expression |
ISO |
Ampicillin results in decreased expression of ARRDC4 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 1:122,369,355...122,383,351
Ensembl chr 1:122,369,360...122,383,290
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of ASAH1 protein |
CTD |
PMID:30545405 |
|
NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
Ampicillin results in decreased expression of ASNS mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP1A1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP2A3 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Atp5mf |
ATP synthase membrane subunit f |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5MF protein |
CTD |
PMID:30545405 |
|
NCBI chr12:9,421,665...9,428,236
Ensembl chr12:9,421,579...9,428,236
|
|
G |
Atp5pd |
ATP synthase peripheral stalk subunit d |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5PD protein |
CTD |
PMID:30545405 |
|
NCBI chr10:100,657,700...100,662,960
Ensembl chr10:100,657,708...100,663,479
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5PF protein |
CTD |
PMID:30545405 |
|
NCBI chr11:23,881,594...23,889,581
Ensembl chr11:23,881,592...23,889,119
|
|
G |
B3galt5 |
Beta-1,3-galactosyltransferase 5 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of B3GALT5 protein |
CTD |
PMID:30545405 |
|
NCBI chr11:35,584,273...35,630,922
Ensembl chr11:35,585,220...35,630,917
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases response to substance |
ISO |
BAX results in increased susceptibility to Ampicillin |
CTD |
PMID:15731293 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bpifb2 |
BPI fold containing family B, member 2 |
increases expression |
ISO |
Ampicillin results in increased expression of BPIFB2 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 3:142,356,990...142,377,053
Ensembl chr 3:142,358,051...142,377,044
|
|
G |
Calr |
calreticulin |
increases expression |
ISO |
Ampicillin results in increased expression of CALR mRNA |
CTD |
PMID:21632981 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Car9 |
carbonic anhydrase 9 |
increases expression |
ISO |
Ampicillin results in increased expression of CA9 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression |
ISO |
Ampicillin results in increased expression of CCN1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccpg1 |
cell cycle progression 1 |
decreases expression |
ISO |
Ampicillin results in decreased expression of CCPG1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430
|
|
G |
Cd40 |
CD40 molecule |
increases expression |
ISO |
Ampicillin results in increased expression of CD40 mRNA |
CTD |
PMID:25091725 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression |
ISO |
Ampicillin results in increased expression of CES1 mRNA |
CTD |
PMID:22609641 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Chst15 |
carbohydrate sulfotransferase 15 |
increases expression |
ISO |
Ampicillin results in increased expression of CHST15 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 1:187,028,860...187,107,908
Ensembl chr 1:187,028,970...187,107,707
|
|
G |
Ckb |
creatine kinase B |
increases expression |
ISO |
Ampicillin results in increased expression of CKB mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Clca4 |
chloride channel accessory 4 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CLCA4 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:233,883,625...233,904,993
Ensembl chr 2:233,883,851...233,903,089
|
|
G |
Cldn5 |
claudin 5 |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of CLDN5 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of CLDN5 protein] |
CTD |
PMID:35390362 |
|
NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Cldn7 |
claudin 7 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CLDN7 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171
|
|
G |
Clgn |
calmegin |
decreases expression |
ISO |
Ampicillin results in decreased expression of CLGN mRNA |
CTD |
PMID:21632981 |
|
NCBI chr19:24,695,140...24,728,542
Ensembl chr19:24,696,875...24,728,758
|
|
G |
Clic3 |
chloride intracellular channel 3 |
increases expression |
ISO |
Ampicillin results in increased expression of CLIC3 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 3:8,271,416...8,274,023
Ensembl chr 3:8,272,097...8,274,018
|
|
G |
Cmbl |
carboxymethylenebutenolidase homolog |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CMBL protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:82,569,257...82,591,007
Ensembl chr 2:82,571,888...82,591,009
|
|
G |
Cndp2 |
carnosine dipeptidase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CNDP2 protein |
CTD |
PMID:30545405 |
|
NCBI chr18:78,039,924...78,057,030
Ensembl chr18:78,039,932...78,056,922
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX5A protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781
|
|
G |
Cox6b1 |
cytochrome c oxidase subunit 6B1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX6B1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:85,875,080...85,884,081
Ensembl chr 1:85,875,109...85,884,001 Ensembl chr 2:85,875,109...85,884,001
|
|
G |
Cox7a2 |
cytochrome c oxidase subunit 7A2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX7A2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:80,716,824...80,720,922
Ensembl chr14:51,301,168...51,301,633 Ensembl chr 8:51,301,168...51,301,633
|
|
G |
Cp |
ceruloplasmin |
increases expression |
ISO |
Ampicillin results in increased expression of CP mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
decreases expression |
ISO |
Ampicillin results in decreased expression of CREB3L3 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of CSF2 protein |
CTD |
PMID:31442584 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csta |
cystatin A |
decreases expression |
ISO |
Ampicillin results in decreased expression of CSTA mRNA |
CTD |
PMID:21632981 |
|
NCBI chr11:64,620,483...64,631,488
Ensembl chr11:64,620,483...64,631,488
|
|
G |
Ctsa |
cathepsin A |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CTSA protein |
CTD |
PMID:30545405 |
|
NCBI chr 3:153,569,106...153,574,983
Ensembl chr 3:153,568,381...153,576,215
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
Ampicillin results in increased expression of CXCL2 mRNA |
CTD |
PMID:24747151 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Ampicillin results in decreased expression of CYP1A1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Ampicillin results in decreased expression of CYP24A1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP27A1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2C11 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2d2 |
cytochrome P450, family 2, subfamily d, polypeptide 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2D2 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 7:113,935,138...113,939,209
Ensembl chr 7:113,935,138...113,939,209
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP3A2 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7A1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP8B1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
increases expression |
ISO |
Ampicillin results in increased expression of DKK1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Ampicillin results in increased expression of DUSP1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Dusp7 |
dual specificity phosphatase 7 |
increases expression |
ISO |
Ampicillin results in increased expression of DUSP7 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 8:107,009,369...107,016,404
Ensembl chr 8:107,008,528...107,016,404
|
|
G |
Edn1 |
endothelin 1 |
increases expression |
ISO |
Ampicillin results in increased expression of EDN1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Epcam |
epithelial cell adhesion molecule |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of EPCAM protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127
|
|
G |
Esm1 |
endothelial cell-specific molecule 1 |
decreases expression |
ISO |
Ampicillin results in decreased expression of ESM1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 2:44,876,067...44,884,805
Ensembl chr 2:44,876,067...44,884,804
|
|
G |
Etfa |
electron transfer flavoprotein subunit alpha |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ETFA protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:55,835,115...55,891,890
Ensembl chr 8:55,835,134...55,891,969
|
|
G |
Ezr |
ezrin |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of EZR protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of FASN mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of FASN mRNA |
CTD |
PMID:36464106 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Filip1l |
filamin A interacting protein 1-like |
increases expression |
ISO |
Ampicillin results in increased expression of FILIP1L mRNA |
CTD |
PMID:21632981 |
|
NCBI chr11:42,937,353...43,177,085
Ensembl chr11:42,940,467...43,177,415
|
|
G |
Fxyd1 |
FXYD domain-containing ion transport regulator 1 |
increases expression |
ISO |
Ampicillin results in increased expression of FXYD1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 1:86,287,163...86,291,478
Ensembl chr 1:86,287,165...86,291,278
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
decreases expression |
ISO |
Ampicillin results in decreased expression of GCLC mRNA |
CTD |
PMID:21632981 PMID:26198647 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
decreases expression increases expression |
ISO |
Ampicillin results in decreased expression of GCLM mRNA Ampicillin results in increased expression of GCLM mRNA |
CTD |
PMID:21632981 PMID:22609641 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gfpt2 |
glutamine-fructose-6-phosphate transaminase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GFPT2 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:34,115,005...34,161,329
Ensembl chr10:34,115,052...34,161,329
|
|
G |
Gipc2 |
GIPC PDZ domain containing family, member 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GIPC2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:241,030,764...241,110,236
Ensembl chr 2:241,030,770...241,110,236
|
|
G |
Gng12 |
G protein subunit gamma 12 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GNG12 protein |
CTD |
PMID:30545405 |
|
NCBI chr 4:96,011,118...96,134,767
Ensembl chr 4:96,010,952...96,134,712
|
|
G |
Gpat3 |
glycerol-3-phosphate acyltransferase 3 |
decreases expression |
ISO |
Ampicillin results in decreased expression of GPAT3 mRNA |
CTD |
PMID:21632981 PMID:26198647 |
|
NCBI chr14:8,715,367...8,768,051
Ensembl chr14:8,714,373...8,766,490
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased activity of GPT protein]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased activity of GPT protein |
CTD |
PMID:36464106 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GPX1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GSTA3 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GSTM2 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Hexb |
hexosaminidase subunit beta |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of HEXB protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223
|
|
G |
Hmgb1 |
high mobility group box 1 |
increases expression |
ISO |
Ampicillin results in increased expression of HMGB1 protein |
CTD |
PMID:24747151 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of HMGCR mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of HMGCR mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Ampicillin results in increased expression of HMOX1 mRNA |
CTD |
PMID:25091725 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnph2 |
heterogeneous nuclear ribonucleoprotein H2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of HNRNPH2 protein |
CTD |
PMID:30545405 |
|
NCBI chr X:97,780,890...97,786,846
Ensembl chr X:97,780,785...97,787,041
|
|
G |
Hoxd1 |
homeo box D1 |
increases expression |
ISO |
Ampicillin results in increased expression of HOXD1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 3:59,665,629...59,667,769
Ensembl chr 3:59,665,629...59,667,769
|
|
G |
Hp |
haptoglobin |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of HP protein |
CTD |
PMID:30545405 |
|
NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523
|
|
G |
Ifrd1 |
interferon-related developmental regulator 1 |
decreases expression |
ISO |
Ampicillin results in decreased expression of IFRD1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
increases expression |
ISO |
Ampicillin results in increased expression of IGFBP3 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
[Metronidazole co-treated with Ampicillin co-treated with Neomycin] inhibits the reaction [bisphenol S results in increased expression of IL18 protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased secretion of IL18 protein] |
CTD |
PMID:35390362 PMID:38908815 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
EXP ISO |
Ampicillin inhibits the reaction [Aspirin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B mRNA]]; Ampicillin inhibits the reaction [Aspirin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]]; Ampicillin inhibits the reaction [Celecoxib promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B mRNA]]; Ampicillin inhibits the reaction [Celecoxib promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]] [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of and results in increased secretion of IL1B protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of IL1B mRNA] Ampicillin results in increased expression of IL1B mRNA |
CTD |
PMID:21893697 PMID:24747151 PMID:35390362 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein] |
CTD |
PMID:31442584 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jdp2 |
Jun dimerization protein 2 |
decreases expression |
ISO |
Ampicillin results in decreased expression of JDP2 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 6:105,261,619...105,302,386
Ensembl chr 6:105,261,373...105,301,485
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Ampicillin results in increased expression of JUND mRNA |
CTD |
PMID:21632981 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kng2 |
kininogen 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MAP1 protein |
CTD |
PMID:30545405 |
|
NCBI chr11:77,913,876...77,936,247
Ensembl chr11:77,909,612...78,002,971
|
|
G |
Krt16 |
keratin 16 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of KRT16 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:85,168,357...85,171,816
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LDLR mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LDLR mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lox |
lysyl oxidase |
increases expression |
ISO |
Ampicillin results in increased expression of LOX mRNA |
CTD |
PMID:21632981 |
|
NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LPIN1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of LPIN1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Lyz2 |
lysozyme 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of LYZ2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MAPK3 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Maz |
MYC associated zinc finger protein |
increases expression |
ISO |
Ampicillin results in increased expression of MAZ mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 1:181,629,742...181,635,193
Ensembl chr 1:181,629,729...181,650,408
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Ampicillin inhibits the reaction [Indomethacin results in increased activity of MPO protein] |
CTD |
PMID:11686837 PMID:11991626 PMID:18306037 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mtss2 |
MTSS I-BAR domain containing 2 |
increases expression |
ISO |
Ampicillin results in increased expression of MTSS2 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr19:38,692,793...38,714,575
Ensembl chr19:38,693,194...38,713,507
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of MYD88 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of MYD88 protein] |
CTD |
PMID:35390362 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Myh14 |
myosin heavy chain 14 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MYH14 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:95,096,266...95,158,861
Ensembl chr 1:95,096,266...95,158,836
|
|
G |
Ndufa13 |
NADH:ubiquinone oxidoreductase subunit A13 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of NDUFA13 protein |
CTD |
PMID:30545405 |
|
NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726
|
|
G |
Ndufab1 |
NADH:ubiquinone oxidoreductase subunit AB1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of NDUFAB1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:176,644,696...176,658,131
Ensembl chr 1:176,644,703...176,658,099
|
|
G |
Nherf2 |
NHERF family PDZ scaffold protein 2 |
increases expression |
ISO |
Ampicillin results in increased expression of NHERF2 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr10:13,662,461...13,672,975
Ensembl chr10:13,662,461...13,673,049
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Ampicillin inhibits the reaction [Aspirin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of NOS2 mRNA]]; Ampicillin inhibits the reaction [Celecoxib promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of NOS2 mRNA]]; Ampicillin inhibits the reaction [Indomethacin results in increased activity of NOS2 protein]; Ampicillin inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA] |
CTD |
PMID:11686837 PMID:12568917 PMID:15610444 PMID:16944022 PMID:18306037 PMID:21893697 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npc2 |
NPC intracellular cholesterol transporter 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of NPC2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:104,397,239...104,418,161
Ensembl chr 6:104,378,644...104,418,155
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
Ampicillin results in increased expression of NQO1 mRNA |
CTD |
PMID:22609641 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of OCLN mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of OCLN protein] |
CTD |
PMID:35390362 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Pa2g4 |
proliferation-associated 2G4 |
increases expression |
ISO |
Ampicillin results in increased expression of PA2G4 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
|
|
G |
Pabpc1l |
poly(A) binding protein, cytoplasmic 1-like |
decreases expression |
ISO |
Ampicillin results in decreased expression of PABPC1L mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 3:152,692,825...152,725,997
Ensembl chr 3:152,693,700...152,725,997
|
|
G |
Pdp2 |
pyruvate dehydrogenase phosphatase catalytic subunit 2 |
increases expression |
ISO |
Ampicillin results in increased expression of PDP2 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr19:386,408...394,068
Ensembl chr19:386,406...394,074
|
|
G |
Pdxkl1 |
pyridoxal kinase like 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of PDXK protein |
CTD |
PMID:30545405 |
|
NCBI chr20:10,162,934...10,192,572
Ensembl chr20:10,164,099...10,192,739
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
increases expression |
ISO |
Ampicillin results in increased expression of PFKFB3 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125
|
|
G |
Pfn1 |
profilin 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PFN1 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631
|
|
G |
Pgam1 |
phosphoglycerate mutase 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PGAM1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:240,723,832...240,731,443
Ensembl chr 1:240,723,920...240,738,452
|
|
G |
Pgc |
progastricsin |
increases expression |
ISO |
Ampicillin results in increased expression of PGC mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 9:13,257,462...13,265,682
Ensembl chr 9:13,257,462...13,265,682
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
EXP |
Ampicillin results in decreased activity of PGD protein |
CTD |
PMID:15558954 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Pir |
pirin |
increases expression |
ISO |
Ampicillin results in increased expression of PIR mRNA |
CTD |
PMID:22609641 |
|
NCBI chr X:30,108,536...30,219,269
Ensembl chr X:30,108,538...30,219,218
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases expression |
ISO |
Ampicillin results in increased expression of PKM mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Plppr1 |
phospholipid phosphatase related 1 |
increases expression |
ISO |
Ampicillin results in increased expression of PLPPR1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 5:63,437,457...63,725,286
Ensembl chr 5:63,437,816...63,763,835
|
|
G |
Pmm2 |
phosphomannomutase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PMM2 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:6,961,521...6,982,913
Ensembl chr10:6,961,709...6,983,098
|
|
G |
Pon1 |
paraoxonase 1 |
decreases activity |
ISO |
Ampicillin results in decreased activity of PON1 protein |
CTD |
PMID:16880604 PMID:31581362 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CA protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:201,485,117...201,488,734
Ensembl chr 1:201,485,085...201,497,327
|
|
G |
Ppp1cb |
protein phosphatase 1 catalytic subunit beta |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CB protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:23,958,813...23,992,841
Ensembl chr 6:23,960,998...23,992,824
|
|
G |
Ppp1cc |
protein phosphatase 1 catalytic subunit gamma |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CC protein |
CTD |
PMID:30545405 |
|
NCBI chr12:34,383,072...34,400,553
Ensembl chr12:34,383,072...34,400,553
|
|
G |
Psma3 |
proteasome 20S subunit alpha 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of PSMA3 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:89,483,741...89,503,775
Ensembl chr 6:89,483,727...89,504,965
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
decreases expression |
ISO |
Ampicillin results in decreased expression of PTGR1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Ampicillin inhibits the reaction [Aspirin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of PTGS2 mRNA]]; Ampicillin inhibits the reaction [Celecoxib promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of PTGS2 mRNA]]; Ampicillin inhibits the reaction [SC 560 results in increased expression of PTGS2 mRNA] |
CTD |
PMID:15610444 PMID:21893697 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptms |
parathymosin |
increases expression |
ISO |
Ampicillin results in increased expression of PTMS mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 4:157,722,384...157,726,575
Ensembl chr 4:157,722,386...157,727,009
|
|
G |
Ralb |
RAS like proto-oncogene B |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RALB protein |
CTD |
PMID:30545405 |
|
NCBI chr13:30,588,036...30,624,199
Ensembl chr13:30,588,033...30,624,202
|
|
G |
Ran |
RAN, member RAS oncogene family |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RAN protein |
CTD |
PMID:30545405 |
|
NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of RELA mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of RELA protein] |
CTD |
PMID:35390362 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rgcc |
regulator of cell cycle |
increases expression |
ISO |
Ampicillin results in increased expression of RGCC mRNA |
CTD |
PMID:21632981 |
|
NCBI chr15:54,662,483...54,675,320
Ensembl chr15:54,662,483...54,681,141
|
|
G |
Rida |
reactive intermediate imine deaminase A homolog |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RIDA protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:65,691,429...65,705,257
Ensembl chr 7:65,691,435...65,705,716
|
|
G |
Rpl30 |
ribosomal protein L30 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPL30 protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:65,648,266...65,651,401
Ensembl chr 7:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363
|
|
G |
Rpn2 |
ribophorin II |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPN2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 3:145,941,787...145,989,271
Ensembl chr 3:145,941,839...145,989,543
|
|
G |
Rps23 |
ribosomal protein S23 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPS23 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:22,079,339...22,080,909
Ensembl chr 2:22,079,302...22,080,918
|
|
G |
Rps27l |
ribosomal protein S27-like |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPS27L protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:67,562,483...67,567,418
Ensembl chr 8:67,562,483...67,567,418
|
|
G |
RT1-DMb |
RT1 class II, locus DMb |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RT1-DMB protein |
CTD |
PMID:30545405 |
|
NCBI chr20:4,693,102...4,700,340
Ensembl chr20:4,693,103...4,700,340
|
|
G |
S100a10 |
S100 calcium binding protein A10 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of S100A10 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:179,221,012...179,229,659
Ensembl chr 2:179,220,887...179,229,661
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of S100A11 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
ISO |
Ampicillin results in increased expression of S100A9 mRNA |
CTD |
PMID:24747151 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Samd1 |
sterile alpha motif domain containing 1 |
increases expression |
ISO |
Ampicillin results in increased expression of SAMD1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr19:24,151,136...24,154,475
Ensembl chr19:24,151,128...24,154,488
|
|
G |
Scarb2 |
scavenger receptor class B, member 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of SCARB2 protein |
CTD |
PMID:30545405 |
|
NCBI chr14:15,558,271...15,609,813
Ensembl chr14:15,558,236...15,609,813
|
|
G |
Serpinb6a |
serpin family B member 6A |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SERPINB6 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:30,871,468...30,989,703
Ensembl chr17:30,871,468...31,014,427
|
|
G |
Sgk2 |
serum/glucocorticoid regulated kinase 2 |
decreases expression |
ISO |
Ampicillin results in decreased expression of SGK2 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 3:151,644,102...151,669,480
Ensembl chr 3:151,644,102...151,669,480
|
|
G |
Shmt2 |
serine hydroxymethyltransferase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SHMT2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:63,358,961...63,364,293
Ensembl chr 7:63,358,961...63,364,236
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
increases expression |
ISO |
Ampicillin results in increased expression of SLC1A2 protein |
CTD |
PMID:17138558 |
|
NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc22a15 |
solute carrier family 22, member 15 |
decreases expression |
ISO |
Ampicillin results in decreased expression of SLC22A15 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 2:189,298,836...189,359,902
Ensembl chr 2:189,298,832...189,358,792
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SLC22A7 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc25a20 |
solute carrier family 25 member 20 |
multiple interactions |
EXP |
Ampicillin binds to and results in decreased activity of SLC25A20 protein; Ampicillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine] |
CTD |
PMID:18452908 |
|
NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
increases expression |
ISO |
Ampicillin results in increased expression of SLC2A3 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472
|
|
G |
Slc3a1 |
solute carrier family 3 member 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SLC3A1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:9,608,169...9,641,881
Ensembl chr 6:9,608,178...9,641,907
|
|
G |
Slc6a14 |
solute carrier family 6 member 14 |
increases expression |
ISO |
Ampicillin results in increased expression of SLC6A14 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr X:112,314,643...112,375,412
Ensembl chr X:112,314,691...112,375,096
|
|
G |
Slc6a8 |
solute carrier family 6 member 8 |
increases expression |
ISO |
Ampicillin results in increased expression of SLC6A8 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr X:151,384,675...151,393,979
Ensembl chr X:151,384,675...151,393,979
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
decreases expression |
ISO |
Ampicillin results in decreased expression of SLC7A11 mRNA |
CTD |
PMID:21632981 PMID:26198647 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Smim14 |
small integral membrane protein 14 |
decreases expression |
ISO |
Ampicillin results in decreased expression of SMIM14 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr14:42,783,361...42,829,762
Ensembl chr14:42,783,332...42,829,760
|
|
G |
Smpd2 |
sphingomyelin phosphodiesterase 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SMPD2 protein |
CTD |
PMID:30545405 |
|
NCBI chr20:44,986,229...44,989,343
Ensembl chr20:44,986,231...44,989,441
|
|
G |
Sqle |
squalene epoxidase |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SQLE mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF1 mRNA]; [Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF1 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Ampicillin co-treated with Metronidazole co-treated with Amphotericin B] results in increased expression of SREBF2 mRNA |
CTD |
PMID:36464106 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Srxn1 |
sulfiredoxin 1 |
decreases expression |
ISO |
Ampicillin results in decreased expression of SRXN1 mRNA |
CTD |
PMID:21632981 PMID:26198647 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Tagln |
transgelin |
increases expression |
ISO |
Ampicillin results in increased expression of TAGLN mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tars1 |
threonyl-tRNA synthetase 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TARS1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:60,368,893...60,387,715
Ensembl chr 2:60,367,796...60,387,717
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression |
ISO |
Ampicillin results in decreased expression of TIMP1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of TJP1 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in decreased expression of TJP1 protein] |
CTD |
PMID:35390362 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TLR4 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TLR4 protein]; TLR4 gene mutant form results in decreased susceptibility to [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] |
CTD |
PMID:35390362 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tm9sf2 |
transmembrane 9 superfamily member 2 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TM9SF2 protein |
CTD |
PMID:30545405 |
|
NCBI chr15:99,201,556...99,254,054
Ensembl chr15:99,201,489...99,254,049
|
|
G |
Tmed10 |
transmembrane p24 trafficking protein 10 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TMED10 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:104,991,843...105,026,705
Ensembl chr 6:104,991,838...105,026,753
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
Ampicillin inhibits the reaction [Aspirin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF mRNA]]; Ampicillin inhibits the reaction [Aspirin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]]; Ampicillin inhibits the reaction [Celecoxib promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF mRNA]]; Ampicillin inhibits the reaction [Celecoxib promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]] [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of and results in increased secretion of TNF protein]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TNF mRNA]; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein] |
CTD |
PMID:21893697 PMID:31442584 PMID:35390362 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tpm4 |
tropomyosin 4 |
increases expression |
ISO |
Ampicillin results in increased expression of TPM4 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr16:17,684,415...17,698,456
Ensembl chr16:17,683,195...17,705,984
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
[Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TRAF6 mRNA]; [Neomycin co-treated with Metronidazole co-treated with Ampicillin co-treated with Vancomycin] inhibits the reaction [Methamphetamine results in increased expression of TRAF6 protein] |
CTD |
PMID:35390362 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Trim16 |
tripartite motif-containing 16 |
increases expression |
ISO |
Ampicillin results in increased expression of TRIM16 mRNA |
CTD |
PMID:22609641 |
|
NCBI chr10:47,485,982...47,509,010
Ensembl chr10:47,486,297...47,551,907
|
|
G |
Ttyh3 |
tweety family member 3 |
increases expression |
ISO |
Ampicillin results in increased expression of TTYH3 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr12:13,996,831...14,025,457
Ensembl chr12:13,997,045...14,025,459
|
|
G |
Tubal3 |
tubulin, alpha-like 3 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TUBAL3 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:66,323,733...66,332,423
Ensembl chr17:66,323,733...66,335,355
|
|
G |
Tubb1 |
tubulin, beta 1 class VI |
increases expression |
ISO |
Ampicillin results in increased expression of TUBB1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 3:163,247,990...163,257,460
Ensembl chr 3:163,247,967...163,256,063
|
|
G |
Tube1 |
tubulin, epsilon 1 |
decreases expression |
ISO |
Ampicillin results in decreased expression of TUBE1 mRNA |
CTD |
PMID:21632981 |
|
NCBI chr20:42,552,390...42,570,324
Ensembl chr20:42,552,437...42,570,314
|
|
G |
Twf1 |
twinfilin actin-binding protein 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TWF1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:125,715,938...125,727,834
Ensembl chr 7:125,716,015...125,727,894
|
|
G |
Txndc5 |
thioredoxin domain containing 5 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TXNDC5 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:26,289,880...26,318,025
Ensembl chr17:26,289,880...26,318,025
|
|
G |
Uqcrc1 |
ubiquinol-cytochrome c reductase core protein 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRC1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:109,589,735...109,601,481
Ensembl chr 8:109,589,706...109,601,480
|
|
G |
Uqcrfs1 |
ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRFS1 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:33,977,908...33,982,478
Ensembl chr17:33,977,921...33,982,479
|
|
G |
Uqcrh |
ubiquinol-cytochrome c reductase hinge protein |
multiple interactions |
EXP |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRH protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:129,545,978...129,554,173
Ensembl chr 5:129,545,984...129,554,242
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Ampicillin inhibits the reaction [Aspirin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of VEGFA mRNA]]; Ampicillin inhibits the reaction [Celecoxib promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of VEGFA mRNA]] |
CTD |
PMID:21893697 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vldlr |
very low density lipoprotein receptor |
decreases expression |
ISO |
Ampicillin results in decreased expression of VLDLR mRNA |
CTD |
PMID:21632981 |
|
NCBI chr 1:224,813,539...224,850,400
Ensembl chr 1:224,814,377...224,845,920
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in decreased expression of ABCB11 mRNA |
CTD |
PMID:34767876 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in increased expression of AKR1B10 mRNA |
CTD |
PMID:34767876 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Casp3 |
caspase 3 |
increases activity |
EXP |
Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP3 protein |
CTD |
PMID:30273099 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity |
EXP |
Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP9 protein |
CTD |
PMID:30273099 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cycs |
cytochrome c, somatic |
increases secretion |
EXP |
Amoxicillin-Potassium Clavulanate Combination results in increased secretion of CYCS protein |
CTD |
PMID:30273099 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:34767876 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:34767876 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
decreases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:34767876 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
increases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in increased expression of FGF19 mRNA |
CTD |
PMID:34767876 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in increased expression of G6PD mRNA |
CTD |
PMID:34767876 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLC mRNA |
CTD |
PMID:34767876 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLM mRNA |
CTD |
PMID:34767876 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
increases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in increased expression of GGT1 protein |
CTD |
PMID:34767876 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
increases activity |
EXP |
Amoxicillin-Potassium Clavulanate Combination results in increased activity of GOT1 protein |
CTD |
PMID:30273099 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases activity |
EXP |
Amoxicillin-Potassium Clavulanate Combination results in increased activity of GPT protein |
CTD |
PMID:30273099 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in increased expression of GPX2 mRNA |
CTD |
PMID:34767876 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in increased expression of GSR mRNA |
CTD |
PMID:34767876 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Me1 |
malic enzyme 1 |
increases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in increased expression of ME1 mRNA |
CTD |
PMID:34767876 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in increased expression of NR0B2 mRNA |
CTD |
PMID:34767876 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:34767876 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc51a |
solute carrier family 51 member A |
decreases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC51A mRNA |
CTD |
PMID:34767876 |
|
NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in increased expression of SLC7A11 mRNA |
CTD |
PMID:34767876 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Tkt |
transketolase |
increases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in increased expression of TKT mRNA |
CTD |
PMID:34767876 |
|
NCBI chr16:5,723,764...5,748,702
Ensembl chr16:5,723,762...5,748,698
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
Amoxicillin-Potassium Clavulanate Combination results in increased expression of TXNRD1 mRNA |
CTD |
PMID:34767876 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
Aztreonam results in increased expression of ABCC2 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
ISO |
Aztreonam results in increased expression of ABCG5 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
ISO |
Aztreonam results in increased expression of ABCG8 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
decreases expression |
ISO |
Aztreonam results in decreased expression of NPC1L1 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
increases expression |
ISO |
Aztreonam results in increased expression of NR5A2 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
RT1-Ha |
RT1 class II, locus Ha |
affects expression |
ISO |
Aztreonam affects the expression of HLA-DPA1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,760,631...4,770,662
Ensembl chr20:4,760,118...4,770,244
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
increases expression |
ISO |
Aztreonam results in increased expression of SLC10A1 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
decreases expression |
ISO |
Aztreonam results in decreased expression of SLC10A2 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc51b |
SLC51 subunit beta |
decreases expression |
ISO |
Aztreonam results in decreased expression of SLC51B mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases activity multiple interactions |
EXP ISO |
Penicillin G results in increased activity of ABCC2 protein Penicillin G promotes the reaction [ABCC2 protein affects the transport of estradiol-17 beta-glucuronide] |
CTD |
PMID:12702717 PMID:15904671 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases transport |
ISO |
ABCC4 protein results in increased transport of Penicillin G |
CTD |
PMID:17939016 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions increases expression |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of ACACA mRNA Penicillin G results in increased expression of ACACA mRNA |
CTD |
PMID:27503388 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acly |
ATP citrate lyase |
increases expression multiple interactions |
ISO |
Penicillin G results in increased expression of ACLY mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of ACLY mRNA |
CTD |
PMID:27503388 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Afp |
alpha-fetoprotein |
affects expression decreases expression |
ISO |
Penicillin G affects the expression of AFP mRNA Penicillin G results in decreased expression of AFP mRNA |
CTD |
PMID:24737281 PMID:25137620 PMID:26272751 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Anxa8 |
annexin A8 |
decreases expression |
ISO |
Penicillin G results in decreased expression of ANXA8 mRNA |
CTD |
PMID:24737281 |
|
NCBI chr16:9,397,144...9,412,072
Ensembl chr16:9,397,113...9,412,043
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Penicillin G results in increased expression of ATF3 mRNA |
CTD |
PMID:27965148 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of CCL2 mRNA Penicillin G results in increased expression of CCL2 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of CCR2 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions increases expression |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of CD36 mRNA Penicillin G results in increased expression of CD36 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
Penicillin G results in increased expression of CD86 protein |
CTD |
PMID:19665512 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cer1 |
cerberus 1, DAN family BMP antagonist |
increases expression |
ISO |
Penicillin G results in increased expression of CER1 mRNA |
CTD |
PMID:26272751 |
|
NCBI chr 5:97,306,427...97,309,783
Ensembl chr 5:97,306,431...97,309,783
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression |
ISO |
Penicillin G results in increased expression of CES1 mRNA |
CTD |
PMID:22609641 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of CPT1A mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of CRP mRNA |
CTD |
PMID:27503388 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cs |
citrate synthase |
multiple interactions increases expression |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of CS mRNA Penicillin G results in increased expression of CS mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Dcn |
decorin |
decreases expression |
ISO |
Penicillin G results in decreased expression of DCN mRNA |
CTD |
PMID:24737281 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Defb1 |
defensin beta 1 |
decreases expression multiple interactions |
ISO |
Penicillin G results in decreased expression of DEFB1 mRNA [Penicillin G co-treated with Erythromycin] results in decreased expression of DEFB1 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr16:70,298,862...70,313,604
Ensembl chr16:70,298,863...70,313,604
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of DGAT1 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of DGAT2 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of FABP1 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions increases expression |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of FASN mRNA Penicillin G results in increased expression of FASN mRNA |
CTD |
PMID:27503388 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Frzb |
frizzled-related protein |
decreases expression |
ISO |
Penicillin G results in decreased expression of FRZB mRNA |
CTD |
PMID:24737281 |
|
NCBI chr 3:65,332,274...65,365,208
Ensembl chr 3:65,332,277...65,365,208
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
Penicillin G results in increased expression of GCLM mRNA |
CTD |
PMID:22609641 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
increases expression multiple interactions |
ISO |
Penicillin G results in increased expression of GPAM mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of GPAM mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639
|
|
G |
Hdac7 |
histone deacetylase 7 |
increases expression |
ISO |
Penicillin G results in increased expression of HDAC7 mRNA |
CTD |
PMID:26272751 |
|
NCBI chr 7:128,923,918...128,961,926
Ensembl chr 7:128,923,920...128,962,072
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases expression |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of IFNG mRNA Penicillin G results in increased expression of IFNG mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf2 |
insulin-like growth factor 2 |
decreases expression |
ISO |
Penicillin G results in decreased expression of IGF2 mRNA |
CTD |
PMID:24737281 |
|
NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
decreases expression |
ISO |
Penicillin G results in decreased expression of IGFBP5 mRNA |
CTD |
PMID:24737281 |
|
NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Il18 |
interleukin 18 |
increases expression |
ISO |
Penicillin G results in increased expression of IL18 protein |
CTD |
PMID:23063874 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression multiple interactions |
ISO |
Penicillin G results in increased expression of IL1A mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of IL1A mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Penicillin G results in increased expression of IL1B mRNA |
CTD |
PMID:22609641 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of IL6 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Penicillin G results in increased expression of JUN mRNA |
CTD |
PMID:26272751 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kdr |
kinase insert domain receptor |
increases expression decreases expression |
ISO |
Penicillin G results in increased expression of KDR mRNA Penicillin G results in decreased expression of KDR mRNA |
CTD |
PMID:25137620 PMID:26272751 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Lbp |
lipopolysaccharide binding protein |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of LBP mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586
|
|
G |
Mesp1 |
mesoderm posterior bHLH transcription factor 1 |
decreases expression |
ISO |
Penicillin G results in decreased expression of MESP1 mRNA |
CTD |
PMID:26272751 |
|
NCBI chr 1:133,738,357...133,739,875
Ensembl chr 1:133,738,357...133,739,875
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
decreases expression |
ISO |
Penicillin G results in decreased expression of MMP1 mRNA |
CTD |
PMID:24737281 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression multiple interactions |
ISO |
Penicillin G results in increased expression of MTTP mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of MTTP mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Muc2 |
mucin 2, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in decreased expression of MUC2 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
ISO |
Penicillin G results in increased expression of MYC mRNA |
CTD |
PMID:26272751 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nefm |
neurofilament medium chain |
affects expression |
ISO |
Penicillin G affects the expression of NEFM mRNA |
CTD |
PMID:25137620 |
|
NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755
|
|
G |
Nes |
nestin |
increases expression affects expression |
EXP ISO |
Penicillin G results in increased expression of NES protein Penicillin G affects the expression of NES mRNA |
CTD |
PMID:16137769 PMID:16369854 PMID:25137620 |
|
NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions increases expression |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of NFKB1 mRNA Penicillin G results in increased expression of NFKB1 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
Penicillin G results in increased expression of NQO1 mRNA |
CTD |
PMID:22609641 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
EXP |
Penicillin G results in decreased activity of PGD protein |
CTD |
PMID:15558954 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Pir |
pirin |
increases expression |
ISO |
Penicillin G results in increased expression of PIR mRNA |
CTD |
PMID:22609641 |
|
NCBI chr X:30,108,536...30,219,269
Ensembl chr X:30,108,538...30,219,218
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
decreases expression |
ISO |
Penicillin G results in decreased expression of PNPLA6 mRNA |
CTD |
PMID:25137620 |
|
NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734
|
|
G |
Reg3g |
regenerating family member 3 gamma |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in decreased expression of REG3G mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723
|
|
G |
Retnlb |
resistin like beta |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in decreased expression of RETNLB mRNA |
CTD |
PMID:27503388 |
|
NCBI chr11:51,983,482...51,985,368
Ensembl chr11:51,983,483...51,985,368
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions increases expression |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of SCD1 mRNA Penicillin G results in increased expression of SCD1 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Shh |
sonic hedgehog signaling molecule |
increases expression |
ISO |
Penicillin G results in increased expression of SHH mRNA |
CTD |
PMID:26272751 |
|
NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
|
|
G |
Slc22a12 |
solute carrier family 22 member 12 |
multiple interactions |
ISO |
Potassium promotes the reaction [SLC22A12 protein results in increased uptake of Penicillin G] |
CTD |
PMID:15284287 |
|
NCBI chr 1:203,845,039...203,852,496
Ensembl chr 1:203,845,048...203,853,555
|
|
G |
Slc22a20 |
solute carrier family 22 member 20 |
multiple interactions |
ISO |
Penicillin G inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:16478971 |
|
NCBI chr 1:203,257,374...203,273,854
Ensembl chr 1:203,257,374...203,273,822
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
multiple interactions |
ISO |
Penicillin G inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:11602689 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
multiple interactions increases uptake |
EXP ISO |
Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]; Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of Famotidine]; Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of Ranitidine]; Probenecid inhibits the reaction [SLC22A8 protein results in increased uptake of Penicillin G]; tranilast inhibits the reaction [SLC22A8 protein results in increased uptake of Penicillin G] resveratrol inhibits the reaction [SLC22A8 protein results in increased uptake of Penicillin G] |
CTD |
PMID:10224140 PMID:15319347 PMID:17255469 PMID:27377006 PMID:35019195 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc27a2 |
solute carrier family 27 member 2 |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of SLC27A2 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208
|
|
G |
Slco3a1 |
solute carrier organic anion transporter family, member 3a1 |
multiple interactions |
ISO |
Penicillin G promotes the reaction [SLCO3A1 protein results in increased uptake of simvastatin acid] |
CTD |
PMID:28887287 |
|
NCBI chr 1:128,106,232...128,388,043
Ensembl chr 1:128,106,228...128,387,925
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of SREBF1 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of TLR4 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of TNF mRNA Penicillin G results in increased expression of TNF mRNA |
CTD |
PMID:27503388 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trim16 |
tripartite motif-containing 16 |
increases expression |
ISO |
Penicillin G results in increased expression of TRIM16 mRNA |
CTD |
PMID:22609641 |
|
NCBI chr10:47,485,982...47,509,010
Ensembl chr10:47,486,297...47,551,907
|
|
G |
Ttr |
transthyretin |
decreases expression |
ISO |
Penicillin G results in decreased expression of TTR mRNA |
CTD |
PMID:24737281 |
|
NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
|
|
G |
Wnt3 |
Wnt family member 3 |
increases expression |
ISO |
Penicillin G results in increased expression of WNT3 mRNA |
CTD |
PMID:26272751 |
|
NCBI chr10:88,680,198...88,724,170
Ensembl chr10:88,680,248...88,724,099
|
|
|
G |
Apeh |
acylaminoacyl-peptide hydrolase |
multiple interactions decreases activity |
ISO |
Carbapenems inhibits the reaction [APEH protein results in increased metabolism of valproic acid glucuronide] Carbapenems results in decreased activity of APEH protein |
CTD |
PMID:20551238 |
|
NCBI chr 8:108,773,791...108,782,903
Ensembl chr 8:108,773,794...108,782,933
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Cefaclor inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Cefaclor results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
ISO |
Cefaclor results in increased expression of CYP3A4 mRNA; Cefaclor results in increased expression of CYP3A4 protein |
CTD |
PMID:18505790 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
multiple interactions |
ISO |
Cefaclor inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:16098483 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
increases uptake multiple interactions |
ISO |
SLC22A8 protein results in increased uptake of Cefaclor Cefaclor inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:16098483 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
ISO |
Cefadroxil results in increased expression of CYP3A4 mRNA; Cefadroxil results in increased expression of CYP3A4 protein |
CTD |
PMID:18505790 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
RT1-M3-1 |
RT1 class Ib, locus M3, gene 1 |
affects expression |
ISO |
Cefadroxil affects the expression of HLA-G mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117
|
|
|
G |
Aadac |
arylacetamide deacetylase |
increases expression |
EXP |
Cephaloridine results in increased expression of AADAC mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:144,163,436...144,186,086
Ensembl chr 2:144,135,319...144,174,734
|
|
G |
Aass |
aminoadipate-semialdehyde synthase |
decreases expression |
EXP |
Cephaloridine results in decreased expression of AASS mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:51,606,461...51,663,136
Ensembl chr 4:51,606,462...51,663,136
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
increases expression |
EXP |
Cephaloridine results in increased expression of ABCB1B mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of ABCC2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Acmsd |
aminocarboxymuconate semialdehyde decarboxylase |
decreases expression |
EXP |
Cephaloridine results in decreased expression of ACMSD mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:39,200,412...39,245,954
Ensembl chr13:39,200,314...39,245,209
|
|
G |
Acot9 |
acyl-CoA thioesterase 9 |
increases expression |
EXP |
Cephaloridine results in increased expression of ACOT9 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr X:40,073,197...40,123,573
Ensembl chr X:40,064,810...40,123,559
|
|
G |
Acsm5 |
acyl-CoA synthetase medium-chain family member 5 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of ACSM5 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:173,870,873...173,896,838
Ensembl chr 1:173,863,041...173,898,588
|
|
G |
Adam8 |
ADAM metallopeptidase domain 8 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of ADAM8 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:194,776,559...194,789,330
Ensembl chr 1:194,770,060...194,788,801
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
increases expression |
EXP |
Cephaloridine results in increased expression of ADGRE1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Adora2a |
adenosine A2a receptor |
increases expression |
EXP |
Cephaloridine results in increased expression of ADORA2A mRNA |
CTD |
PMID:18500788 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Adra1d |
adrenoceptor alpha 1D |
increases expression |
EXP |
Cephaloridine results in increased expression of ADRA1D mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354
|
|
G |
Aftph |
aftiphilin |
decreases expression |
EXP |
Cephaloridine results in decreased expression of AFTPH mRNA |
CTD |
PMID:18500788 |
|
NCBI chr14:94,871,429...94,925,625
Ensembl chr14:94,871,429...94,925,376
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
increases expression |
EXP |
Cephaloridine results in increased expression of AKR1B1 mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1d1 |
aldo-keto reductase family 1, member D1 |
increases expression |
EXP |
Cephaloridine results in increased expression of AKR1D1 mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of ALAS1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
increases expression |
EXP |
Cephaloridine results in increased expression of ALDH3A1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Aldh3b1 |
aldehyde dehydrogenase 3 family, member B1 |
increases expression |
EXP |
Cephaloridine results in increased expression of ALDH3B1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:201,145,309...201,162,675
Ensembl chr 1:201,145,309...201,163,921
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
affects expression |
EXP |
Cephaloridine affects the expression of ALDOA mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Amer2 |
APC membrane recruitment protein 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of AMER2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr15:34,525,352...34,535,660
Ensembl chr15:34,524,542...34,528,455
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of AMIGO2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695
|
|
G |
Ampd1 |
adenosine monophosphate deaminase 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of AMPD1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:190,598,707...190,619,938
Ensembl chr 2:190,598,700...190,619,938
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
increases expression |
EXP |
Cephaloridine results in increased expression of AMPD3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
EXP |
Cephaloridine results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Anln |
anillin, actin binding protein |
decreases expression |
EXP |
Cephaloridine results in decreased expression of ANLN mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:20,858,227...20,921,602
Ensembl chr 8:20,858,228...20,921,538
|
|
G |
Anxa13 |
annexin A13 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of ANXA13 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:89,884,356...89,936,907
Ensembl chr 7:89,884,356...89,936,907
|
|
G |
Anxa7 |
annexin A7 |
increases expression |
EXP |
Cephaloridine results in increased expression of ANXA7 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr15:3,821,798...3,849,659
Ensembl chr15:3,821,845...3,849,385
|
|
G |
Apcs |
amyloid P component, serum |
decreases expression |
EXP |
Cephaloridine results in decreased expression of APCS mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:85,373,219...85,374,195
Ensembl chr13:85,373,220...85,374,298
|
|
G |
Apoa4 |
apolipoprotein A4 |
increases expression |
EXP |
Cephaloridine results in increased expression of APOA4 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apob |
apolipoprotein B |
increases expression |
EXP |
Cephaloridine results in increased expression of APOB mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoc2 |
apolipoprotein C2 |
increases expression |
EXP |
Cephaloridine results in increased expression of APOC2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476
|
|
G |
Apold1 |
apolipoprotein L domain containing 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of APOLD1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:167,768,437...167,825,706
Ensembl chr 4:167,818,271...167,825,706
|
|
G |
Arfgef3 |
ARFGEF family member 3 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of ARFGEF3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:13,245,578...13,404,319
Ensembl chr 1:13,244,830...13,404,084
|
|
G |
Arhgap35 |
Rho GTPase activating protein 35 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of ARHGAP35 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:77,202,436...77,319,298
Ensembl chr 1:77,202,436...77,319,298
|
|
G |
Arid5a |
AT-rich interaction domain 5A |
increases expression |
EXP |
Cephaloridine results in increased expression of ARID5A mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:38,534,612...38,549,467
Ensembl chr 9:38,534,590...38,547,597
|
|
G |
Asf1b |
anti-silencing function 1B histone chaperone |
increases expression |
EXP |
Cephaloridine results in increased expression of ASF1B mRNA |
CTD |
PMID:18500788 |
|
NCBI chr19:24,181,024...24,195,604
Ensembl chr19:24,181,028...24,195,549
|
|
G |
Ash1l |
ASH1 like histone lysine methyltransferase |
decreases expression |
EXP |
Cephaloridine results in decreased expression of ASH1L mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:174,346,267...174,483,057
Ensembl chr 2:174,346,150...174,483,055
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
EXP |
Cephaloridine results in increased expression of ASNS mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atad1 |
ATPase family, AAA domain containing 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of ATAD1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:230,544,227...230,610,524
Ensembl chr 1:230,544,047...230,596,548
|
|
G |
Atad2 |
ATPase family, AAA domain containing 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of ATAD2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738
|
|
G |
Atf3 |
activating transcription factor 3 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of ATF3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atl1 |
atlastin GTPase 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of ATL1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 6:88,377,168...88,475,242
Ensembl chr 6:88,377,239...88,475,204
|
|
G |
Atp11c |
ATPase phospholipid transporting 11C |
decreases expression |
EXP |
Cephaloridine results in decreased expression of ATP11C mRNA |
CTD |
PMID:18500788 |
|
NCBI chr X:138,564,459...138,752,116
Ensembl chr X:138,565,836...138,751,204
|
|
G |
Atp12a |
ATPase H+/K+ transporting non-gastric alpha2 subunit |
increases expression |
EXP |
Cephaloridine results in increased expression of ATP12A mRNA |
CTD |
PMID:18500788 |
|
NCBI chr15:30,443,571...30,468,229
Ensembl chr15:30,443,571...30,468,229
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
EXP |
Cephaloridine results in decreased expression of AURKB mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
B3galt2 |
Beta-1,3-galactosyltransferase 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of B3GALT2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:55,389,406...55,398,419
Ensembl chr13:55,389,406...55,398,419
|
|
G |
B3gnt7 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of B3GNT7 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:86,956,220...86,960,171
Ensembl chr 9:86,956,220...86,960,170
|
|
G |
Bag3 |
BAG cochaperone 3 |
increases expression |
EXP |
Cephaloridine results in increased expression of BAG3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of BAK1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of BARD1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265
|
|
G |
Batf |
basic leucine zipper ATF-like transcription factor |
increases expression |
EXP |
Cephaloridine results in increased expression of BATF mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 6:105,353,715...105,376,051
Ensembl chr 6:105,353,715...105,376,051
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
affects expression |
EXP |
Cephaloridine affects the expression of BCL2L1 mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bex2 |
brain expressed X-linked 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of BEX1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr X:99,019,847...99,021,375
Ensembl chr X:99,019,000...99,021,503
|
|
G |
Bex4 |
brain expressed, X-linked 4 |
increases expression |
EXP |
Cephaloridine results in increased expression of BEX4 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr X:99,131,985...99,133,417
Ensembl chr X:99,131,942...99,133,531
|
|
G |
Bhlhe41 |
basic helix-loop-helix family, member e41 |
increases expression |
EXP |
Cephaloridine results in increased expression of BHLHE41 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:178,834,264...178,838,618
Ensembl chr 4:178,834,271...178,838,468
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
increases expression |
EXP |
Cephaloridine results in increased expression of BIRC3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Blvrb |
biliverdin reductase B |
increases expression |
EXP |
Cephaloridine results in increased expression of BLVRB mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375
|
|
G |
Bpi |
bactericidal/permeability-increasing protein |
increases expression |
EXP |
Cephaloridine results in increased expression of BPI mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:146,909,626...146,936,487
Ensembl chr 3:146,909,629...146,936,221
|
|
G |
Brip1 |
BRCA1 interacting helicase 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of BRIP1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:70,907,266...71,031,502
Ensembl chr10:70,907,371...71,030,324
|
|
G |
Bsnd |
barttin CLCNK type accessory subunit beta |
increases expression |
EXP |
Cephaloridine results in increased expression of BSND mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 5:121,251,774...121,260,571
Ensembl chr 5:121,251,774...121,260,571
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of BTG2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
decreases expression |
EXP |
Cephaloridine results in decreased expression of BUB1B mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
|
|
G |
C10h16orf89 |
similar to human chromosome 16 open reading frame 89 |
increases expression |
EXP |
Cephaloridine results in increased expression of C10H16ORF89 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:10,361,909...10,371,046
Ensembl chr10:10,361,948...10,371,046
|
|
G |
C1qtnf1 |
C1q and TNF related 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of C1QTNF1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:103,660,319...103,681,662
Ensembl chr10:103,660,327...103,681,660
|
|
G |
C5 |
complement C5 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of C5 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
C6 |
complement C6 |
increases expression |
EXP |
Cephaloridine results in increased expression of C6 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:53,846,028...53,921,279
Ensembl chr 2:53,851,985...53,921,275
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
increases expression |
EXP |
Cephaloridine results in increased expression of CACNA1H mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
|
|
G |
Cacng3 |
calcium voltage-gated channel auxiliary subunit gamma 3 |
increases expression |
EXP |
Cephaloridine results in increased expression of CACNG3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:177,201,361...177,297,019
Ensembl chr 1:177,201,288...177,297,024
|
|
G |
Calb1 |
calbindin 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of CALB1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
|
|
G |
Calb2 |
calbindin 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CALB2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438
|
|
G |
Calr |
calreticulin |
increases expression |
EXP |
Cephaloridine results in increased expression of CALR mRNA |
CTD |
PMID:18172885 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Camkv |
CaM kinase-like vesicle-associated |
increases expression |
EXP |
Cephaloridine results in increased expression of CAMKV mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:108,626,821...108,641,169
Ensembl chr 8:108,626,821...108,641,169
|
|
G |
Canx |
calnexin |
increases expression |
EXP |
Cephaloridine results in increased expression of CANX mRNA |
CTD |
PMID:18172885 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Cat |
catalase |
affects expression |
EXP |
Cephaloridine affects the expression of CAT protein |
CTD |
PMID:9933756 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccdc113 |
coiled-coil domain containing 113 |
increases expression |
EXP |
Cephaloridine results in increased expression of CCDC113 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr19:9,497,000...9,516,917
Ensembl chr19:9,496,886...9,516,923
|
|
G |
Ccl17 |
C-C motif chemokine ligand 17 |
increases expression |
EXP |
Cephaloridine results in increased expression of CCL17 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr19:10,202,128...10,203,903
Ensembl chr19:10,202,128...10,203,819
|
|
G |
Ccl19 |
C-C motif chemokine ligand 19 |
increases expression |
EXP |
Cephaloridine results in increased expression of CCL19 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 5:56,963,364...56,965,308
Ensembl chr 5:56,963,364...56,965,308
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression |
EXP |
Cephaloridine results in increased expression of CCL20 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl28 |
C-C motif chemokine ligand 28 |
increases expression |
EXP |
Cephaloridine results in increased expression of CCL28 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CCL3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CCL4 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CCN2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CCNA2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CCNB1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CCNB2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
EXP |
Cephaloridine results in increased expression of CCNE1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccne2 |
cyclin E2 |
increases expression |
EXP |
Cephaloridine results in increased expression of CCNE2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Cd52 |
CD52 molecule |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CD52 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 5:146,319,789...146,321,348
Ensembl chr 5:146,319,969...146,321,348
|
|
G |
Cd72 |
Cd72 molecule |
increases expression |
EXP |
Cephaloridine results in increased expression of CD72 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 5:57,697,361...57,704,980
Ensembl chr 5:57,697,367...57,704,725
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
EXP |
Cephaloridine results in increased expression of CD86 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CDC42 mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdc45 |
cell division cycle 45 |
increases expression |
EXP |
Cephaloridine results in increased expression of CDC45 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619
|
|
G |
Cdc6 |
cell division cycle 6 |
increases expression |
EXP |
Cephaloridine results in increased expression of CDC6 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdca2 |
cell division cycle associated 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CDCA2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr15:41,895,946...41,942,226
Ensembl chr15:41,895,901...41,941,611
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CDK1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkl1 |
cyclin dependent kinase like 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CDKL1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 6:88,224,154...88,273,434
Ensembl chr 6:88,224,143...88,270,276
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CDKN1A mRNA |
CTD |
PMID:18500788 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CDKN1B mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdt1 |
chromatin licensing and DNA replication factor 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of CDT1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659
|
|
G |
Ceacam16 |
CEA cell adhesion molecule 16, tectorial membrane component |
increases expression |
EXP |
Cephaloridine results in increased expression of CEACAM16 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:79,514,975...79,524,871
Ensembl chr 1:79,514,975...79,524,871
|
|
G |
Cenpk |
centromere protein K |
increases expression |
EXP |
Cephaloridine results in increased expression of CENPK mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:35,360,390...35,421,372
Ensembl chr 2:35,360,132...35,385,706
|
|
G |
Cenpq |
centromere protein Q |
increases expression |
EXP |
Cephaloridine results in increased expression of CENPQ mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:19,957,122...19,972,807
Ensembl chr 9:19,957,048...19,972,789
|
|
G |
Cesl1 |
carboxylesterase-like 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CESL1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr19:22,670,709...23,006,329
Ensembl chr19:22,670,712...22,712,608
|
|
G |
Chaf1a |
chromatin assembly factor 1 subunit A |
increases expression |
EXP |
Cephaloridine results in increased expression of CHAF1A mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654
|
|
G |
Chaf1b |
chromatin assembly factor 1 subunit B |
increases expression |
EXP |
Cephaloridine results in increased expression of CHAF1B mRNA |
CTD |
PMID:18500788 |
|
NCBI chr11:33,200,894...33,221,076
Ensembl chr11:33,200,981...33,221,070
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CHD4 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:157,898,503...157,931,632
Ensembl chr 4:157,899,391...157,931,541
|
|
G |
Chd6 |
chromodomain helicase DNA binding protein 6 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CHD6 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:149,596,509...149,757,765
Ensembl chr 3:149,596,509...149,757,755
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of CHEK1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chst7 |
carbohydrate sulfotransferase 7 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CHST7 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr X:2,396,260...2,432,828
Ensembl chr X:2,393,874...2,432,840
|
|
G |
Chtf18 |
chromosome transmission fidelity factor 18 |
increases expression |
EXP |
Cephaloridine results in increased expression of CHTF18 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:14,743,006...14,751,044
Ensembl chr10:14,742,621...14,751,050
|
|
G |
Cilp |
cartilage intermediate layer protein |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CILP mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:65,777,281...65,792,251
Ensembl chr 8:65,777,281...65,792,251
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of CITED2 mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897
|
|
G |
Ckap2 |
cytoskeleton associated protein 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CKAP2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913
|
|
G |
Cldn14 |
claudin 14 |
increases expression |
EXP |
Cephaloridine results in increased expression of CLDN14 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr11:33,232,281...33,329,440
Ensembl chr11:33,232,220...33,329,171
|
|
G |
Clstn2 |
calsyntenin 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CLSTN2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:98,020,406...98,637,232
Ensembl chr 8:98,021,666...98,637,731
|
|
G |
Cmip |
c-Maf-inducing protein |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CMIP mRNA |
CTD |
PMID:18500788 |
|
NCBI chr19:45,304,597...45,510,653
Ensembl chr19:45,304,031...45,508,709
|
|
G |
Cndp1 |
carnosine dipeptidase 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CNDP1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr18:77,984,886...78,030,837
Ensembl chr18:77,984,907...78,007,765
|
|
G |
Col4a4 |
collagen type IV alpha 4 chain |
decreases expression |
EXP |
Cephaloridine results in decreased expression of COL4A4 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:83,833,173...83,875,436
Ensembl chr 9:83,755,515...83,875,876
|
|
G |
Col7a1 |
collagen type VII alpha 1 chain |
increases expression |
EXP |
Cephaloridine results in increased expression of COL7A1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:109,604,877...109,637,249
Ensembl chr 8:109,604,861...109,637,252
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
increases expression |
EXP |
Cephaloridine results in increased expression of CPT1B mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Crabp1 |
cellular retinoic acid binding protein 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of CRABP1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:55,138,363...55,159,360
Ensembl chr 8:55,151,285...55,159,360
|
|
G |
Crebbp |
CREB binding protein |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CREBBP mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Cry1 |
cryptochrome circadian regulator 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of CRY1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CXCL1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
EXP |
Cephaloridine results in increased expression of CXCL10 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl13 |
C-X-C motif chemokine ligand 13 |
increases expression |
EXP |
Cephaloridine results in increased expression of CXCL13 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
increases expression |
EXP |
Cephaloridine results in increased expression of CXCL14 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839
|
|
G |
Cxxc4 |
CXXC finger protein 4 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CXXC4 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:222,664,148...222,689,365
Ensembl chr 2:222,664,771...222,689,365
|
|
G |
Cyb5a |
cytochrome b5 type A |
increases expression |
EXP |
Cephaloridine results in increased expression of CYB5A mRNA |
CTD |
PMID:18172885 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of CYP1B1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CYP24A1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of CYP2C mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of CYP7B1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Dctpp1 |
dCTP pyrophosphatase 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of DCTPP1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:181,877,440...181,880,833
Ensembl chr 1:181,877,437...181,880,839
|
|
G |
Dctpp1-ps2 |
dCTP pyrophosphatase 1, pseudogene 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of DCTPP1-PS2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr16:1,392,967...1,393,868
|
|
G |
Ddc |
dopa decarboxylase |
decreases expression |
EXP |
Cephaloridine results in decreased expression of DDC mRNA |
CTD |
PMID:18500788 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of DDIT4 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
increases expression |
EXP |
Cephaloridine results in increased expression of DDIT4L mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375
|
|
G |
Ddx39a |
DExD-box helicase 39A |
increases expression |
EXP |
Cephaloridine results in increased expression of DDX39A mRNA |
CTD |
PMID:18500788 |
|
NCBI chr19:24,418,743...24,427,422
Ensembl chr19:24,418,114...24,426,954
|
|
G |
Ddx6 |
DEAD-box helicase 6 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of DDX6 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:44,931,127...44,967,773
Ensembl chr 8:44,931,974...44,964,405
|
|
G |
Decr2 |
2,4-dienoyl-CoA reductase 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of DECR2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:15,104,907...15,113,281
Ensembl chr10:15,002,926...15,118,479
|
|
G |
Dhrs2l1 |
dehydrogenase/reductase member 2 like 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of DHRS2L1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr15:28,635,197...28,638,087
Ensembl chr15:28,635,197...28,638,087
|
|
G |
Dlgap1 |
DLG associated protein 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of DLGAP1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:109,857,500...110,726,817
Ensembl chr 9:110,167,448...110,726,817
|
|
G |
Dnah7 |
dynein, axonemal, heavy chain 7 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of DNAH7 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:54,960,235...55,266,529
Ensembl chr 9:54,960,440...55,262,297
|
|
G |
Dnah9 |
dynein, axonemal, heavy chain 9 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of DNAH9 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:50,496,174...50,864,909
Ensembl chr10:50,497,688...50,864,949
|
|
G |
Dnase1l3 |
deoxyribonuclease 1L3 |
increases expression |
EXP |
Cephaloridine results in increased expression of DNASE1L3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr15:16,922,335...16,948,322
Ensembl chr15:16,922,335...16,948,317
|
|
G |
Dnph1 |
2'-deoxynucleoside 5'-phosphate N-hydrolase 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of DNPH1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:14,481,296...14,484,034
Ensembl chr 9:14,481,066...14,484,022
|
|
G |
Donson |
DNA replication fork stabilization factor DONSON |
increases expression |
EXP |
Cephaloridine results in increased expression of DONSON mRNA |
CTD |
PMID:18500788 |
|
NCBI chr11:30,919,834...30,933,150
Ensembl chr11:30,923,239...30,932,889
|
|
G |
Dpf1 |
double PHD fingers 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of DPF1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:84,602,212...84,615,954
Ensembl chr 1:84,602,336...84,615,950
|
|
G |
Dscc1 |
DNA replication and sister chromatid cohesion 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of DSCC1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212
|
|
G |
Dsg2 |
desmoglein 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of DSG2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr18:11,846,207...11,904,630
Ensembl chr18:11,846,183...11,904,156
|
|
G |
Dtx4 |
deltex E3 ubiquitin ligase 4 |
increases expression |
EXP |
Cephaloridine results in increased expression of DTX4 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:209,457,719...209,545,163
Ensembl chr 1:209,460,735...209,492,818
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
affects expression |
EXP |
Cephaloridine affects the expression of DUSP6 mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Dusp7 |
dual specificity phosphatase 7 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of DUSP7 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:107,009,369...107,016,404
Ensembl chr 8:107,008,528...107,016,404
|
|
G |
Dusp9 |
dual specificity phosphatase 9 |
increases expression |
EXP |
Cephaloridine results in increased expression of DUSP9 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr X:151,351,897...151,355,822
Ensembl chr X:151,351,897...151,355,821
|
|
G |
E2f8 |
E2F transcription factor 8 |
increases expression |
EXP |
Cephaloridine results in increased expression of E2F8 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Edrf1 |
erythroid differentiation regulatory factor 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of EDRF1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:188,441,514...188,478,743
Ensembl chr 1:188,441,634...188,478,701
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of EEF2 mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of EGR1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of EGR2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Eif4h |
eukaryotic translation initiation factor 4H |
increases expression |
EXP |
Cephaloridine results in increased expression of EIF4H mRNA |
CTD |
PMID:18172885 |
|
NCBI chr12:22,083,155...22,099,876
Ensembl chr12:22,082,835...22,099,876
|
|
G |
Elf3 |
E74 like ETS transcription factor 3 |
increases expression |
EXP |
Cephaloridine results in increased expression of ELF3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481
|
|
G |
Emb |
embigin |
increases expression |
EXP |
Cephaloridine results in increased expression of EMB mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:49,070,509...49,125,042
Ensembl chr 2:49,069,087...49,125,050
|
|
G |
Eme1 |
essential meiotic structure-specific endonuclease 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of EME1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:79,586,718...79,595,515
Ensembl chr10:79,586,729...79,595,435
|
|
G |
Enc1 |
ectodermal-neural cortex 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of ENC1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713
|
|
G |
Eno2 |
enolase 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of ENO2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Entrep1 |
endosomal transmembrane epsin interactor 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of ENTREP1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:221,592,500...221,646,603
Ensembl chr 1:221,592,503...221,646,758
|
|
G |
Espl1 |
extra spindle pole bodies like 1, separase |
decreases expression |
EXP |
Cephaloridine results in decreased expression of ESPL1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:133,424,027...133,450,984
Ensembl chr 7:133,424,130...133,450,984
|
|
G |
Exo1 |
exonuclease 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of EXO1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
|
|
G |
F13b |
coagulation factor XIII B chain |
decreases expression |
EXP |
Cephaloridine results in decreased expression of F13B mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:51,130,908...51,156,383
Ensembl chr13:51,130,920...51,156,381
|
|
G |
Fam111a |
FAM111 trypsin like peptidase A |
decreases expression |
EXP |
Cephaloridine results in decreased expression of FAM111A mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547
|
|
G |
Fancd2 |
FA complementation group D2 |
increases expression |
EXP |
Cephaloridine results in increased expression of FANCD2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
|
|
G |
Fbln1 |
fibulin 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of FBLN1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
|
|
G |
Fbp2 |
fructose-bisphosphatase 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of FBP2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr17:2,236,088...2,253,702
Ensembl chr17:2,236,336...2,253,698
|
|
G |
Fbxo5 |
F-box protein 5 |
increases expression |
EXP |
Cephaloridine results in increased expression of FBXO5 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:42,196,068...42,202,437
Ensembl chr 1:42,196,068...42,202,437
|
|
G |
Fcgr2a |
Fc gamma receptor 2A |
increases expression |
EXP |
Cephaloridine results in increased expression of FCGR2A mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967
|
|
G |
Fcgr2b |
Fc gamma receptor 2B |
increases expression |
EXP |
Cephaloridine results in increased expression of FCGR2B mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:83,191,253...83,207,778
Ensembl chr13:83,193,163...83,207,778
|
|
G |
Fcgr3a |
Fc gamma receptor 3A |
increases expression |
EXP |
Cephaloridine results in increased expression of FCGR3A mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:83,249,905...83,259,921
Ensembl chr13:83,249,872...83,259,921
|
|
G |
Fcnb |
ficolin B |
increases expression |
EXP |
Cephaloridine results in increased expression of FCNB mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:11,393,713...11,402,198
Ensembl chr 3:11,393,739...11,402,151
|
|
G |
Fen1 |
flap structure-specific endonuclease 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of FEN1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003
|
|
G |
Fgb |
fibrinogen beta chain |
increases expression |
EXP |
Cephaloridine results in increased expression of FGB mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
|
|
G |
Fgf17 |
fibroblast growth factor 17 |
increases expression |
EXP |
Cephaloridine results in increased expression of FGF17 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr15:45,711,498...45,717,622
Ensembl chr15:45,711,998...45,717,063
|
|
G |
Fgl2 |
fibrinogen-like 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of FGL2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:13,710,566...13,716,207
Ensembl chr 4:13,710,575...13,716,207
|
|
G |
Fhdc1 |
FH2 domain containing 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of FHDC1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:169,790,917...169,829,580
Ensembl chr 2:169,790,947...169,827,896
|
|
G |
Filip1 |
filamin A interacting protein 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of FILIP1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:80,761,283...80,956,556
Ensembl chr 8:80,764,604...80,922,549
|
|
G |
Folh1 |
folate hydrolase 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of FOLH1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:140,428,101...140,501,563
Ensembl chr 1:140,428,101...140,501,379
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
EXP |
Cephaloridine results in decreased expression of FOS mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxe1 |
forkhead box E1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of FOXE1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 5:60,630,027...60,632,835
Ensembl chr 5:60,630,027...60,632,835
|
|
G |
Foxq1 |
forkhead box Q1 |
increases expression |
EXP |
Cephaloridine results in increased expression of FOXQ1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr17:32,912,744...32,915,377
Ensembl chr17:32,912,744...32,915,377 Ensembl chr17:32,912,744...32,915,377
|
|
G |
Fyco1 |
FYVE and coiled-coil domain autophagy adaptor 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of FYCO1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:123,412,105...123,479,315
Ensembl chr 8:123,412,112...123,479,021
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of G6PC1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases expression |
EXP |
Cephaloridine results in increased expression of G6PD mRNA |
CTD |
PMID:18500788 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
EXP |
Cephaloridine results in increased expression of GADD45A mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Galnt13 |
polypeptide N-acetylgalactosaminyltransferase 13 |
increases expression |
EXP |
Cephaloridine results in increased expression of GALNT13 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:38,903,695...39,560,683
Ensembl chr 3:38,974,490...39,558,803
|
|
G |
Ganc |
glucosidase, alpha; neutral C |
decreases expression |
EXP |
Cephaloridine results in decreased expression of GANC mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:107,353,369...107,406,104
Ensembl chr 3:107,353,369...107,405,241
|
|
G |
Garin4 |
golgi associated RAB2 interactor family member 4 |
increases expression |
EXP |
Cephaloridine results in increased expression of GARIN4 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:102,742,988...102,745,168
Ensembl chr13:102,742,988...102,745,168
|
|
G |
Gba3 |
glucosylceramidase beta 3 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of GBA3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr14:60,574,974...60,721,411
Ensembl chr14:60,574,976...60,721,653
|
|
G |
Gda |
guanine deaminase |
increases expression |
EXP |
Cephaloridine results in increased expression of GDA mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416
|
|
G |
Gdf15 |
growth differentiation factor 15 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of GDF15 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gfra2 |
GDNF family receptor alpha 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of GFRA2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr15:45,941,841...46,033,715
Ensembl chr15:45,941,828...46,033,714
|
|
G |
Gins2 |
GINS complex subunit 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of GINS2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr19:48,626,770...48,639,523
Ensembl chr19:48,626,770...48,639,339
|
|
G |
Gins4 |
GINS complex subunit 4 |
increases expression |
EXP |
Cephaloridine results in increased expression of GINS4 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr16:68,787,572...68,799,938
Ensembl chr16:68,767,339...68,802,273
|
|
G |
Gmnn |
geminin, DNA replication inhibitor |
increases expression |
EXP |
Cephaloridine results in increased expression of GMNN mRNA |
CTD |
PMID:18500788 |
|
NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054
|
|
G |
Gna14 |
G protein subunit alpha 14 |
increases expression |
EXP |
Cephaloridine results in increased expression of GNA14 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:213,716,020...213,897,423
|
|
G |
Gpnmb |
glycoprotein nmb |
increases expression |
EXP |
Cephaloridine results in increased expression of GPNMB mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
|
|
G |
Gpr135 |
G protein-coupled receptor 135 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of GPR135 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 6:90,627,533...90,630,661
Ensembl chr 6:90,629,178...90,630,551
|
|
G |
Gpr19 |
G protein-coupled receptor 19 |
increases expression |
EXP |
Cephaloridine results in increased expression of GPR19 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:167,710,944...167,739,232
Ensembl chr 4:167,710,666...167,741,036
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of GPX2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of GRIA3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression |
EXP |
Cephaloridine results in increased expression of GSR mRNA |
CTD |
PMID:18172885 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of GSTA2 mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
increases expression |
EXP |
Cephaloridine results in increased expression of GSTA5 mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of GSTM1 mRNA |
CTD |
PMID:18172885 PMID:18500788 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of GSTP1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gxylt1 |
glucoside xylosyltransferase 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of GXYLT1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:124,400,896...124,434,682
Ensembl chr 7:124,400,896...124,434,699
|
|
G |
H1f1 |
H1.1 linker histone, cluster member |
increases expression |
EXP |
Cephaloridine results in increased expression of H1F1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr17:41,366,268...41,367,011
Ensembl chr17:41,366,268...41,367,011
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
decreases expression |
EXP |
Cephaloridine results in decreased expression of HADH mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Haus8 |
HAUS augmin-like complex, subunit 8 |
increases expression |
EXP |
Cephaloridine results in increased expression of HAUS8 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr16:17,930,819...17,945,254
Ensembl chr16:17,930,820...17,945,237
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of HAVCR1 mRNA |
CTD |
PMID:18500788 PMID:20305092 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hck |
HCK proto-oncogene, Src family tyrosine kinase |
increases expression |
EXP |
Cephaloridine results in increased expression of HCK mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693
|
|
G |
Hebp1 |
heme binding protein 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of HEBP1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:167,974,316...168,003,854
Ensembl chr 4:167,974,319...168,003,854
|
|
G |
Hebp2 |
heme binding protein 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of HEBP2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:13,194,982...13,201,777
Ensembl chr 1:13,194,982...13,201,777
|
|
G |
Hells |
helicase, lymphoid specific |
increases expression |
EXP |
Cephaloridine results in increased expression of HELLS mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844
|
|
G |
Hepacam2 |
HEPACAM family member 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of HEPACAM2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:31,446,195...31,480,859
Ensembl chr 4:31,446,169...31,480,953
|
|
G |
Hjv |
hemojuvelin BMP co-receptor |
decreases expression |
EXP |
Cephaloridine results in decreased expression of HJV mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:184,065,944...184,069,851
Ensembl chr 2:184,065,970...184,069,850
|
|
G |
Hlx |
H2.0-like homeobox |
decreases expression |
EXP |
Cephaloridine results in decreased expression of HLX mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:96,280,335...96,285,750
Ensembl chr13:96,280,339...96,285,750
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of HMGCS2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of HMOX1 mRNA |
CTD |
PMID:18172885 PMID:18500788 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hmx3 |
H6 family homeobox 3 |
increases expression |
EXP |
Cephaloridine results in increased expression of HMX3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:186,313,237...186,315,201
Ensembl chr 1:186,313,063...186,315,201
|
|
G |
Hnrnpa1 |
heterogeneous nuclear ribonucleoprotein A1 |
increases expression |
EXP |
Cephaloridine results in increased expression of HNRNPA1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:134,375,318...134,381,610
Ensembl chr 7:134,375,150...134,381,609
|
|
G |
Hnrnpa1-ps28 |
heterogeneous nuclear ribonucleoprotein A1, pseudogene 28 |
increases expression |
EXP |
Cephaloridine results in increased expression of HNRNPA1-PS28 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr X:107,752,105...107,759,183
|
|
G |
Hrg |
histidine-rich glycoprotein |
decreases expression |
EXP |
Cephaloridine results in decreased expression of HRG mRNA |
CTD |
PMID:18500788 |
|
NCBI chr11:78,054,488...78,069,402
Ensembl chr11:78,054,498...78,069,389
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of HSD17B2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of HSD3B1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of HSP90AA1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
increases expression |
EXP |
Cephaloridine results in increased expression of HSPA1A mRNA |
CTD |
PMID:18500788 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
increases expression |
EXP |
Cephaloridine results in increased expression of HSPA1B mRNA |
CTD |
PMID:18500788 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of HSPH1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Htatip2 |
HIV-1 Tat interactive protein 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of HTATIP2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629
|
|
G |
Htr5b |
5-hydroxytryptamine (serotonin) receptor 5B |
increases expression |
EXP |
Cephaloridine results in increased expression of HTR5B mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:32,686,911...32,699,835
Ensembl chr13:32,687,042...32,699,835
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of ICAM1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Idi2l3 |
isopentenyl-diphosphate delta isomerase 2 like 3 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of IDI2L3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr17:61,518,138...61,535,484
Ensembl chr17:61,519,390...61,531,603
|
|
G |
Ier3 |
immediate early response 3 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of IER3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583
|
|
G |
Ifitm10 |
interferon induced transmembrane protein 10 |
increases expression |
EXP |
Cephaloridine results in increased expression of IFITM10 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:197,507,501...197,524,180
Ensembl chr 1:197,507,503...197,525,151
|
|
G |
Il18 |
interleukin 18 |
increases expression |
EXP |
Cephaloridine results in increased expression of IL18 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
EXP |
Cephaloridine results in decreased expression of IL1B mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il20ra |
interleukin 20 receptor subunit alpha |
decreases expression |
EXP |
Cephaloridine results in decreased expression of IL20RA mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:14,424,215...14,494,226
Ensembl chr 1:14,451,228...14,493,602
|
|
G |
Inhbb |
inhibin subunit beta B |
decreases expression |
EXP |
Cephaloridine results in decreased expression of INHBB mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832
|
|
G |
Itpka |
inositol-trisphosphate 3-kinase A |
increases expression |
EXP |
Cephaloridine results in increased expression of ITPKA mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:106,726,036...106,734,601
Ensembl chr 3:106,726,036...106,734,600
|
|
G |
Itpkb |
inositol-trisphosphate 3-kinase B |
increases expression |
EXP |
Cephaloridine results in increased expression of ITPKB mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:92,069,160...92,164,281
Ensembl chr13:92,069,216...92,162,004
|
|
G |
Jade2 |
jade family PHD finger 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of JADE2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:36,075,239...36,124,210
Ensembl chr10:36,078,917...36,116,984
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Cephaloridine results in increased expression of JUN mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
decreases expression increases expression |
EXP |
Cephaloridine results in decreased expression of JUNB mRNA Cephaloridine results in increased expression of JUNB mRNA |
CTD |
PMID:18172885 PMID:18500788 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Kbtbd11 |
kelch repeat and BTB domain containing 11 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of KBTBD11 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr16:74,618,291...74,638,010
Ensembl chr16:74,615,792...74,637,736
|
|
G |
Kcnh1 |
potassium voltage-gated channel subfamily H member 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of KCNH1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:103,722,140...104,024,762
Ensembl chr13:103,722,245...104,024,740
|
|
G |
Kcnj15 |
potassium inwardly-rectifying channel, subfamily J, member 15 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of KCNJ15 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr11:34,577,397...34,621,725
Ensembl chr11:34,577,363...34,621,952
|
|
G |
Kctd1 |
potassium channel tetramerization domain containing 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of KCTD1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr18:6,122,390...6,316,434
Ensembl chr18:6,122,390...6,317,393
|
|
G |
Kgd4 |
alpha-ketoglutarate dehydrogenase subunit 4 |
increases expression |
EXP |
Cephaloridine results in increased expression of KGD4 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:31,870,549...31,878,335
Ensembl chr 2:31,870,551...31,880,730
|
|
G |
Kif18a |
kinesin family member 18A |
decreases expression |
EXP |
Cephaloridine results in decreased expression of KIF18A mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:95,764,388...95,824,756
Ensembl chr 3:95,764,388...95,824,582
|
|
G |
Kif2c |
kinesin family member 2C |
decreases expression |
EXP |
Cephaloridine results in decreased expression of KIF2C mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637
|
|
G |
Klf7 |
KLF transcription factor 7 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of KLF7 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:65,433,683...65,526,372
Ensembl chr 9:65,437,167...65,526,261
|
|
G |
Klhl25 |
kelch-like family member 25 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of KLHL25 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:129,724,894...129,750,142
Ensembl chr 1:129,722,026...129,750,227
|
|
G |
Knstrn |
kinetochore-localized astrin/SPAG5 binding protein |
decreases expression |
EXP |
Cephaloridine results in decreased expression of KNSTRN mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:105,800,762...105,820,555
Ensembl chr 3:105,800,954...105,820,715
|
|
G |
Kntc1 |
kinetochore associated 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of KNTC1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr12:32,769,020...32,839,617
Ensembl chr12:32,769,020...32,839,561
|
|
G |
Lama2 |
laminin subunit alpha 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of LAMA2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:17,672,675...18,320,641
Ensembl chr 1:17,672,536...18,320,530
|
|
G |
Lamb3 |
laminin subunit beta 3 |
increases expression |
EXP |
Cephaloridine results in increased expression of LAMB3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405
|
|
G |
Lars1 |
leucyl-tRNA synthetase 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of LARS1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr18:34,201,555...34,256,003
Ensembl chr18:34,201,549...34,255,931
|
|
G |
Lcor |
ligand dependent nuclear receptor corepressor |
decreases expression |
EXP |
Cephaloridine results in decreased expression of LCOR mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:240,298,565...240,405,627
Ensembl chr 1:240,298,563...240,402,448
|
|
G |
Lect2 |
leukocyte cell-derived chemotaxin 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of LECT2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr17:8,044,759...8,050,983
Ensembl chr17:8,044,759...8,050,983
|
|
G |
Lgals2 |
galectin 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of LGALS2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:110,403,171...110,410,046
Ensembl chr 7:110,403,173...110,404,802
|
|
G |
Lgals3 |
galectin 3 |
increases expression |
EXP |
Cephaloridine results in increased expression of LGALS3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
|
|
G |
Lhx3 |
LIM homeobox 3 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of LHX3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:9,026,432...9,035,122
Ensembl chr 3:9,027,425...9,034,480
|
|
G |
Lig1 |
DNA ligase 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of LIG1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:74,165,688...74,204,400
Ensembl chr 1:74,165,842...74,204,413
|
|
G |
Lmnb1 |
lamin B1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of LMNB1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502
|
|
G |
Lratd1 |
LRAT domain containing 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of LRATD1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 6:36,916,969...36,922,143
Ensembl chr 6:36,913,469...36,922,319
|
|
G |
Lrrn3 |
leucine rich repeat neuronal 3 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of LRRN3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 6:58,489,060...58,520,322
Ensembl chr 6:58,489,010...58,520,330
|
|
G |
Maf |
MAF bZIP transcription factor |
decreases expression |
EXP |
Cephaloridine results in decreased expression of MAF mRNA |
CTD |
PMID:18500788 |
|
NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of MAP3K1 mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463
|
|
G |
Map3k12 |
mitogen activated protein kinase kinase kinase 12 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of MAP3K12 mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 7:133,630,267...133,648,464
Ensembl chr 7:133,630,835...133,640,789
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation increases activity |
EXP |
Thymic Factor, Circulating inhibits the reaction [Cephaloridine results in increased phosphorylation of MAPK1 protein] Cephaloridine results in increased activity of MAPK1 protein |
CTD |
PMID:16154539 PMID:16272694 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases activity multiple interactions increases phosphorylation |
EXP |
Cephaloridine results in increased activity of MAPK3 protein Thymic Factor, Circulating inhibits the reaction [Cephaloridine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16154539 PMID:16272694 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8ip3 |
mitogen-activated protein kinase 8 interacting protein 3 |
increases expression |
EXP |
Cephaloridine results in increased expression of MAPK8IP3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:13,918,417...13,958,335
Ensembl chr10:13,918,400...13,958,273
|
|
G |
Masp2 |
MBL associated serine protease 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of MASP2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 5:159,035,892...159,049,561
Ensembl chr 5:159,035,911...159,049,580
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of MCM2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
increases expression |
EXP |
Cephaloridine results in increased expression of MCM3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
increases expression |
EXP |
Cephaloridine results in increased expression of MCM5 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389
|
|
G |
Mcm6 |
minichromosome maintenance complex component 6 |
increases expression |
EXP |
Cephaloridine results in increased expression of MCM6 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
increases expression |
EXP |
Cephaloridine results in increased expression of MCM7 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Mcm8 |
minichromosome maintenance 8 homologous recombination repair factor |
increases expression |
EXP |
Cephaloridine results in increased expression of MCM8 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:120,086,741...120,117,008
Ensembl chr 3:120,086,763...120,117,008
|
|
G |
Mesp1 |
mesoderm posterior bHLH transcription factor 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of MESP1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:133,738,357...133,739,875
Ensembl chr 1:133,738,357...133,739,875
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases expression |
EXP |
Cephaloridine results in increased expression of MET mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mgll |
monoglyceride lipase |
decreases expression |
EXP |
Cephaloridine results in decreased expression of MGLL mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of MKI67 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
increases expression |
EXP |
Cephaloridine results in increased expression of MMP12 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp16 |
matrix metallopeptidase 16 |
increases expression |
EXP |
Cephaloridine results in increased expression of MMP16 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 5:31,312,280...31,556,276
Ensembl chr 5:31,312,280...31,548,388
|
|
G |
Mnd1 |
meiotic nuclear divisions 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of MND1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:169,433,523...169,496,081
Ensembl chr 2:169,433,540...169,496,096
|
|
G |
Mns1 |
meiosis-specific nuclear structural 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of MNS1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:73,148,877...73,169,570
Ensembl chr 8:73,148,877...73,176,925
|
|
G |
Mpst |
mercaptopyruvate sulfurtransferase |
decreases expression |
EXP |
Cephaloridine results in decreased expression of MPST mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:109,955,581...109,963,155
Ensembl chr 7:109,955,675...109,963,141
|
|
G |
Mpv17l |
MPV17 mitochondrial inner membrane protein like |
decreases expression |
EXP |
Cephaloridine results in decreased expression of MPV17L mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:1,988,451...2,025,300
Ensembl chr10:1,988,136...2,007,649
|
|
G |
Mt1 |
metallothionein 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of MT1A mRNA |
CTD |
PMID:18172885 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049
|
|
G |
Mthfd1l |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like |
increases expression |
EXP |
Cephaloridine results in increased expression of MTHFD1L mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:40,443,926...40,632,911
Ensembl chr 1:40,444,008...40,632,905
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
increases expression |
EXP |
Cephaloridine results in increased expression of MTHFD2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Myom3 |
myomesin 3 |
increases expression |
EXP |
Cephaloridine results in increased expression of MYOM3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 5:147,992,737...148,043,282
Ensembl chr 5:147,992,737...148,043,274
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of NCOR2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319
|
|
G |
Nek6 |
NIMA-related kinase 6 |
increases expression |
EXP |
Cephaloridine results in increased expression of NEK6 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:22,284,269...22,356,302
Ensembl chr 3:22,284,279...22,395,990
|
|
G |
Nfil3 |
nuclear factor, interleukin 3 regulated |
increases expression |
EXP |
Cephaloridine results in increased expression of NFIL3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases expression |
EXP |
Cephaloridine results in decreased expression of NFKBIA mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbiz |
NFKB inhibitor zeta |
decreases expression |
EXP |
Cephaloridine results in decreased expression of NFKBIZ mRNA |
CTD |
PMID:18500788 |
|
NCBI chr11:44,782,676...44,810,722
Ensembl chr11:44,782,676...44,810,723
|
|
G |
Ngfr |
nerve growth factor receptor |
increases expression |
EXP |
Cephaloridine results in increased expression of NGFR mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nhp2 |
NHP2 ribonucleoprotein |
increases expression |
EXP |
Cephaloridine results in increased expression of NHP2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:35,877,057...35,880,399
Ensembl chr10:35,877,054...35,882,545
|
|
G |
Ninj2 |
ninjurin 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of NINJ2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:153,306,439...153,408,618
Ensembl chr 4:153,306,553...153,408,617
|
|
G |
Nipsnap3a |
nipsnap homolog 3A (C. elegans) |
increases expression |
EXP |
Cephaloridine results in increased expression of NIPSNAP3B mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 5:67,613,993...67,625,067
Ensembl chr 5:67,614,036...67,669,700
|
|
G |
Nme4 |
NME/NM23 nucleoside diphosphate kinase 4 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of NME4 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:15,114,624...15,118,479
Ensembl chr10:15,002,926...15,118,479
|
|
G |
Nop56 |
NOP56 ribonucleoprotein |
increases expression |
EXP |
Cephaloridine results in increased expression of NOP56 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:117,476,963...117,481,847
Ensembl chr 3:117,477,053...117,481,841
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of NQO1 mRNA |
CTD |
PMID:18172885 PMID:18500788 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of NR1D1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705
|
|
G |
Nrm |
nurim |
increases expression |
EXP |
Cephaloridine results in increased expression of NRM mRNA |
CTD |
PMID:18500788 |
|
NCBI chr20:2,888,321...2,892,804
Ensembl chr20:2,877,567...2,891,802
|
|
G |
Nudt11 |
nudix hydrolase 11 |
increases expression |
EXP |
Cephaloridine results in increased expression of NUDT10 mRNA; Cephaloridine results in increased expression of NUDT11 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr X:16,326,775...16,333,396
Ensembl chr X:16,326,598...16,333,145
|
|
G |
Oprl1 |
opioid related nociceptin receptor 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of OPRL1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:168,831,934...168,839,920
Ensembl chr 3:168,834,003...168,839,920
|
|
G |
Or2w6 |
olfactory receptor family 2 subfamily W member 6 |
increases expression |
EXP |
Cephaloridine results in increased expression of OR2W6 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr17:42,906,458...42,907,396
Ensembl chr17:42,904,951...42,919,599
|
|
G |
Or52b2 |
olfactory receptor family 52 subfamily B member 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of OR52B2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:159,695,507...159,696,475
Ensembl chr 1:159,694,964...159,701,227
|
|
G |
Or52k1 |
olfactory receptor family 52 subfamily K member 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of OR52K1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:157,037,381...157,038,325
Ensembl chr 1:157,037,381...157,038,325
|
|
G |
Orc6 |
origin recognition complex, subunit 6 |
increases expression |
EXP |
Cephaloridine results in increased expression of ORC6 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr19:21,757,867...21,765,638
Ensembl chr19:21,757,866...21,765,662
|
|
G |
Osbpl8 |
oxysterol binding protein-like 8 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of OSBPL8 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:46,596,944...46,749,888
Ensembl chr 7:46,596,983...46,749,888
|
|
G |
Osmr |
oncostatin M receptor |
increases expression |
EXP |
Cephaloridine results in increased expression of OSMR mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:55,907,119...55,961,373
Ensembl chr 2:55,907,132...55,961,262
|
|
G |
Oxgr1 |
oxoglutarate receptor 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of OXGR1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr15:97,145,947...97,146,960
Ensembl chr15:97,144,293...97,166,612
|
|
G |
Padi6 |
peptidyl arginine deiminase 6 |
increases expression |
EXP |
Cephaloridine results in increased expression of PADI6 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 5:153,021,855...153,037,443
Ensembl chr 5:153,021,965...153,037,414
|
|
G |
Palb2 |
partner and localizer of BRCA2 |
increases expression |
EXP |
Cephaloridine results in increased expression of PALB2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:176,665,076...176,689,053
Ensembl chr 1:176,665,076...176,688,990
|
|
G |
Pask |
PAS domain containing serine/threonine kinase |
increases expression |
EXP |
Cephaloridine results in increased expression of PASK mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:93,844,275...93,886,036
Ensembl chr 9:93,844,278...93,885,111
|
|
G |
Pbk |
PDZ binding kinase |
decreases expression |
EXP |
Cephaloridine results in decreased expression of PBK mRNA |
CTD |
PMID:18500788 |
|
NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014
|
|
G |
Pcdh7 |
protocadherin 7 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of PCDH7 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr14:52,471,801...52,901,696
Ensembl chr14:52,475,610...52,902,051 Ensembl chr14:52,475,610...52,902,051
|
|
G |
Pcdh9 |
protocadherin 9 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of PCDH9 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr15:69,340,108...70,237,531
Ensembl chr15:69,340,645...70,237,538
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of PCK1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pclaf |
PCNA clamp associated factor |
increases expression |
EXP |
Cephaloridine results in increased expression of PCLAF mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994 Ensembl chr 8:66,420,587...66,432,994
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression |
EXP |
Cephaloridine results in increased expression of PCNA mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
increases expression |
EXP |
Cephaloridine results in increased expression of PDIA4 mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107
|
|
G |
Pfn3 |
profilin 3 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of PFN3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr17:9,217,595...9,218,122
|
|
G |
Pipox |
pipecolic acid and sarcosine oxidase |
increases expression |
EXP |
Cephaloridine results in increased expression of PIPOX mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:62,769,874...62,783,484
Ensembl chr10:62,769,900...62,782,370
|
|
G |
Pir |
pirin |
increases expression |
EXP |
Cephaloridine results in increased expression of PIR mRNA |
CTD |
PMID:18500788 |
|
NCBI chr X:30,108,536...30,219,269
Ensembl chr X:30,108,538...30,219,218
|
|
G |
Pkhd1 |
PKHD1 ciliary IPT domain containing fibrocystin/polyductin |
decreases expression |
EXP |
Cephaloridine results in decreased expression of PKHD1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:22,547,396...23,037,443
Ensembl chr 9:22,549,513...23,037,381
|
|
G |
Pkmyt1 |
protein kinase, membrane associated tyrosine/threonine 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of PKMYT1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:12,748,221...12,758,995
Ensembl chr10:12,748,237...12,758,995
|
|
G |
Pla1a |
phospholipase A1 member A |
increases expression |
EXP |
Cephaloridine results in increased expression of PLA1A mRNA |
CTD |
PMID:18500788 |
|
NCBI chr11:62,320,112...62,357,779
Ensembl chr11:62,320,493...62,357,779
|
|
G |
Plek2 |
pleckstrin 2 |
increases expression |
EXP |
Cephaloridine results in increased expression of PLEK2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 6:97,700,123...97,719,417
Ensembl chr 6:97,701,106...97,719,326
|
|
G |
Plekha5 |
pleckstrin homology domain containing A5 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of PLEKHA5 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:173,333,891...173,503,546
Ensembl chr 4:173,334,055...173,503,546
|
|
G |
Plk1 |
polo-like kinase 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of PLK1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Pola2 |
DNA polymerase alpha 2, accessory subunit |
increases expression |
EXP |
Cephaloridine results in increased expression of POLA2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:203,227,183...203,251,350
Ensembl chr 1:203,203,388...203,251,348
|
|
G |
Pold1 |
DNA polymerase delta 1, catalytic subunit |
increases expression |
EXP |
Cephaloridine results in increased expression of POLD1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:95,025,462...95,041,559
Ensembl chr 1:95,025,499...95,036,465
|
|
G |
Pole |
DNA polymerase epsilon, catalytic subunit |
increases expression |
EXP |
Cephaloridine results in increased expression of POLE mRNA |
CTD |
PMID:18500788 |
|
NCBI chr12:46,345,420...46,393,984
Ensembl chr12:46,345,420...46,393,939
|
|
G |
Ppa1 |
inorganic pyrophosphatase 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of PPA1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr20:29,590,733...29,617,711
Ensembl chr20:29,590,707...29,619,215
|
|
G |
Ppm1j |
protein phosphatase, Mg2+/Mn2+ dependent, 1J |
increases expression |
EXP |
Cephaloridine results in increased expression of PPM1J mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 2:192,278,597...192,283,883
Ensembl chr 2:192,278,517...192,283,882
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
decreases expression |
EXP |
Cephaloridine results in decreased expression of PPP1R15A mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of PRC1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Prim1 |
DNA primase subunit 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of PRIM1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:446,342...462,526
Ensembl chr 7:431,805...462,526
|
|
G |
Prkar1b |
protein kinase cAMP-dependent type I regulatory subunit beta |
increases expression |
EXP |
Cephaloridine results in increased expression of PRKAR1B mRNA |
CTD |
PMID:18500788 |
|
NCBI chr12:15,492,233...15,624,942
Ensembl chr12:15,511,801...15,624,942
|
|
G |
Prodh2 |
proline dehydrogenase 2 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of PRODH2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:85,753,558...85,767,165
Ensembl chr 1:85,753,644...85,767,162
|
|
G |
Prrx1 |
paired related homeobox 1 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of PRRX1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr13:75,600,777...75,671,896
Ensembl chr13:75,601,706...75,670,866
|
|
G |
Prss35 |
serine protease 35 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of PRSS35 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 8:87,714,449...87,731,009
Ensembl chr 8:87,714,966...87,731,009
|
|
G |
Psmb4 |
proteasome 20S subunit beta 4 |
increases expression |
EXP |
Cephaloridine results in increased expression of PSMB4 mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 2:182,442,757...182,445,532
Ensembl chr 2:182,442,756...182,445,746
|
|
G |
Ptbp1 |
polypyrimidine tract binding protein 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of PTBP1 mRNA |
CTD |
PMID:18172885 |
|
NCBI chr 7:9,842,574...9,852,332
Ensembl chr 7:9,842,574...9,852,397
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases expression |
EXP |
Cephaloridine results in increased expression of PTGR1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
G |
Ptpn11 |
protein tyrosine phosphatase, non-receptor type 11 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of PTPN11 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925
|
|
G |
Ptprb |
protein tyrosine phosphatase, receptor type, B |
decreases expression |
EXP |
Cephaloridine results in decreased expression of PTPRB mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 7:51,953,375...52,034,751
Ensembl chr 7:51,930,015...52,034,748
|
|
G |
Ptprn2 |
protein tyrosine phosphatase, receptor type N2 |
increases expression |
EXP |
Cephaloridine results in increased expression of PTPRN2 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 6:137,439,572...138,191,575
Ensembl chr 6:137,439,540...138,191,575
|
|
G |
Ptrh1 |
peptidyl-tRNA hydrolase 1 homolog |
increases expression |
EXP |
Cephaloridine results in increased expression of PTRH1 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 3:16,064,867...16,071,098
Ensembl chr 3:16,064,880...16,070,648
|
|
G |
Pvr |
PVR cell adhesion molecule |
increases expression |
EXP |
Cephaloridine results in increased expression of PVR mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 1:79,561,294...79,576,700
Ensembl chr 1:79,546,879...79,576,715
|
|
G |
Rab11fip3 |
RAB11 family interacting protein 3 |
decreases expression |
EXP |
Cephaloridine results in decreased expression of RAB11FIP3 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr10:15,002,650...15,086,382
Ensembl chr10:15,002,926...15,118,479
|
|
G |
Rab31 |
RAB31, member RAS oncogene family |
decreases expression |
EXP |
Cephaloridine results in decreased expression of RAB31 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 9:105,246,712...105,382,973
Ensembl chr 9:105,246,709...105,381,253
|
|
G |
Rad18 |
RAD18 E3 ubiquitin protein ligase |
increases expression |
EXP |
Cephaloridine results in increased expression of RAD18 mRNA |
CTD |
PMID:18500788 |
|
NCBI chr 4:145,735,654...145,821,102
Ensembl chr 4:145,735,654...145,821,069
|
| |